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ABSTRACT 
THE ROLE OF STREPTOCOCCUS GALLOLYTICUS SUBSPECIES 
GALLOLYTICUS IN COLON CANCER DEVELOPMENT 
Jennifer Lynn Herold 
Supervisory Professor: Yi Xu, Ph.D. 
Colorectal cancer (CRC) is the third most common 
cancer in men and women and is also the third most common 
cause of cancer death. A large body of evidence points 
towards the possibility that bacteria can have a 
significant impact on the development of cancer. It has 
been suggested that Streptococcus gallolyticus subsp. 
gallolyticus, a group D streptococci, may play a role in 
the development of CRC. Sg, formerly referred to as S. 
bovis biotype I, has been shown to be highly associated 
with CRC. In observing patients with either Sg bacteremia 
or endocarditis it was found that 25-80% of patients with 
Sg bacteremia had tumors and 18-62% of patients with Sg 
endocarditis had colonic neoplasias. However, other closely 
related Streptococcal strains, such as S. pasterianus and 
S. infantarius, have not been shown to have this strong 
association with CRC. In fact, it has been shown that 
biotype I is more often associated with CRC (94%) as 
compared to biotype II (18%). This knowledge has important 
	 vii	
clinical implications, and yet little is known about the 
role of Sg on CRC and the underlying mechanisms. Here we 
show that mice treated with Sg had significantly more 
tumors, higher tumor burden and dysplasia grade, and 
increased cell proliferation and β-catenin level in colonic 
crypts compared to mice treated with control bacteria. Sg 
strains that promoted proliferation were also more 
efficient at adhering to CRC cell lines and colonizing a 
mouse model. Additionally, in human patients Sg was highly 
prevalent in CRC patients and tumor tissues had an 
increased Sg burden in comparison to normal adjacent 
tissues. These results provide exciting new information and 
establish a tumor-promoting role of Sg that involves 
specific bacterial and host factors.  
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Chapter 1:  
INTRODUCTION 
Streptococcus gallolyticus subsp. gallolyticus. 
Streptococcus gallolyticus subsp. gallolyticus (Sg) belongs to 
the Streptococcus bovis/Streptococcus equinus complex (SBSEC) 
and was previously known as S. bovis biotype I [1, 2]. This 
organism is a Gram-positive, opportunistic pathogen that 
causes bacteremia and endocarditis in humans. It has also been 
shown to strongly associate with colorectal cancer (CRC), 
however the role Sg plays in the development is unclear [3-
19]. 
Changes in nomenclature. S. bovis belongs to the group D 
streptococci. Since the 1970’s S. bovis has undergone several 
changes in nomenclature, beginning with the reclassification 
of S. bovis into biotypes, based on bacteriological plating 
assays. Biotype I was classified by its ability to ferment 
mannitol, biotype II/1 was mannitol negative and β-
glucuronidase negative, and biotype II/2 was mannitol negative 
and β-glucuronidase positive [20]. In the early 2000s, 
molecular techniques consisting of DNA homology, whole-cell 
protein extracts, and sodA gene sequencing were developed that 
led to a further reclassification of S. bovis. S. bovis 
biotype I is now S. gallolyticus subsp. gallolyticus, S. bovis 
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biotype II/1 is now S. infantarius subsp. infantarius or 
subsp. coli, and S. bovis biotype II/2 is now S. gallolyticus 
subsp. pasteurianus (Table 1)[1, 2]. Unfortunately, these 
changes have not been fully embraced in the literature and 
have led to some discrepancies in S. bovis identification.  
The development of colorectal cancer (CRC). CRC is the 
second to third most common cancer in the world and a leading 
cause of cancer-related death [21, 22]. Approximately 134,490 
new CRC cases and 49,190 deaths are estimated to occur in the 
United States in 2016 [23]. Worldwide, ~ 1.4 million CRC cases 
were diagnosed and ~ 694,000 deaths occurred in 2012 [24]. The 
classical model for the development of CRC is a multi-stage, 
multi-factor process, involving the accumulation of a series 
of mutations over ~20-40 years as illustrated in the well-
known “Vogelgram” [25, 26]. The first step involves mutations 
in the adenomatous polyposis coli (apc) gene, which leads to 
aberrant activation of  β-catenin and the development of early 
adenoma. Mutations in Ras and p53 drive the progression from 
early to late adenoma, and from late adenoma to carcinoma, 
respectively. Each of these stages is also accompanied by a 
number of other genetic and epigenetic alterations including 
loss of heterozygosity and changes in DNA methylation. Studies 
performed in the last decade or so have added new components 
to the picture, and highlighted the contribution of the tumor  
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Table 1:  
 
The milestone of the taxonomy of S. bovis/gallolyticus and the 
closely related members of Group D Streptococci. 
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microenvironment. These new components include inflammatory 
responses, abnormal metabolic activities [27] and microbes [4, 
28, 29]. Inflammatory responses produce bioactive molecules 
that can affect several hallmark capabilities [27]. For 
example, inflammatory mediators can supply growth, survival, 
and proangiogenic factors, ECM-modifying enzymes, and invasion 
and metastasis signals to the tumor microenvironment. 
Alterations in metabolism lead to reprogramming of metabolic 
activities that allow for sustained proliferation and tumor 
growth. Both of these components can be modulated by the 
presence of microbes. 
Microbes and cancer. It is estimated that ~15-20% of 
cancers are linked to infectious agents [30]. This percentage 
is generally higher in developing countries and lower in 
developed countries, such as the United States. The link 
between microbes and cancer was first established in viruses. 
One example is human papilloma virus (HPV), which causes 
nearly all cervical cancers. HPV integrates into the host 
chromosome and interferes with cell cycle control and 
apoptosis through the overexpression of HPV oncoproteins E6 
and E7 [31]. Helicobacter pylori was the first bacterial 
pathogen linked to cancer. Colonization of H. pylori in the 
gastrointestinal tract significantly increases the risk for 
gastric cancer and elimination of it from the gut reduces the 
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risk [6, 32]. H. pylori contributes to cancer development 
through many mechanisms, but most notably by increasing 
inflammation, producing DNA-damaging toxins, and altering β-
catenin signaling [33-37]. 
The colon is frequently exposed to 1014 microorganisms. 
This collection of microbes – the microbiome - has 
increasingly been recognized as an active participant in 
shaping the development of immune responses, modulating 
metabolic activities and nutrient acquisition, and thus 
contributing to the health and disease status of the gut [3]. 
A number of bacterial species have been linked to CRC through 
either epidemiological studies and/or analyses of the gut 
microbiota and have led to a newly coined term- oncomicrobes 
[28]. They include – Enterotoxigenic Bacteroides fragilis, 
Fusobacterium nucleatum, polyketide synthase positive (pks+) 
Escherichia coli, Enterococcus faecalis, etc.  The mechanisms 
utilized by these bacteria to promote tumorigenesis are 
diverse, including producing toxins that damage DNA [38-44], 
aberrant activation of β-catenin signaling [45-51], or 
triggering inflammatory responses that favor tumor growth [28, 
45, 52-58]. Enterococcus faecalis promotes tumorigenesis 
through a bystander effect by activating macrophages, which in 
turn produce DNA damaging clastogens [59].  
	 23	
The recognition that microbial agents are intimately 
involved in the health and disease status of the gut [3] and 
that specific microbes can drive colon tumorigenesis [41, 48, 
50, 60-62] further raise hope that we may be able to exploit 
knowledge about specific tumor-promoting microbes to improve 
cancer diagnosis and treatment by incorporating microbes into 
clinical strategies [4-7, 28, 63]. For example, specific 
microbial antigens may be useful as a diagnostic biomarker for 
CRC. The presence of specific tumor-promoting microbes in the 
colon may require optimized therapeutic regimens that take the 
microbes into consideration. 
S. gallolyticus subsp. gallolyticus bacteremia/ 
endocarditis association with CRC. Although the association of 
S. bovis infections with CRC was first reported in 1951, this 
association was not fully recognized until 1974 when reported 
by Keusch et al.[64]. Numerous case reports and case series 
have documented elevated risks for CRC among patients infected 
with S. bovis or Sg. In a more recent meta-analysis by Boleij 
et al., 52 case reports and 31 case series published in PubMed 
from 1970 to 2010 were reviewed [10]. The analysis found a 
median prevalence of CRC of approximately 39% among patients 
with S. bovis infections. However, not all patients in these 
cases underwent colonoscopies, which may have resulted in 
undetected lesions or small polyps and a subsequent 
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underestimation of the actual prevalence of CRC within the 
patient population. This possible underestimation of patients 
with CRC appears to be supported by further analysis 
investigating patients who were both infected with S. bovis 
and also underwent colonoscopy. In these cases, the prevalence 
of CRC among these patients increased to 60% [10]. 
Additionally, S. bovis bacteremia has been shown to be 
associated with other malignancies, such as tumor lesions in 
the duodenum, gallbladder, pancreas, ovary, uterus, lung, and 
hematopoietic system [14].  
 Boleij et al. also evaluated studies that distinguished 
Sg (S. bovis biotype I) from other biotypes within the S. 
bovis group [10]. They found that Sg bacteremia has a 71% 
association with CRC, while the association between S. bovis 
biotype II bacteremia with CRC is only 17%. Patients with S. 
bovis biotype I infections were more likely to have CRC (33-
71% prevalence) in comparison to the normal population (10-
25%). Additionally, a recent prospective study on 203 
colonoscopy patients found a clear relationship between 
patients positive for S. bovis in the colonic suction fluid 
and presence of malignant tumors and large polyps in the colon 
[65]. Specifically, all 17 malignant tumors diagnosed in this 
cohort were S. bovis positive. Further, there is also evidence 
that a substantial proportion of CRC patients are “silently” 
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infected with Sg. For example, Abdulamir et al. studied 52 CRC 
patients without symptoms of bacteremia and found that 
approximately 33% of tumors and 23% of matched normal colon 
tissues to be Sg-positive when a conventional PCR method was 
used for detection of Sg [66].  
Cause or consequence. Although the association between Sg 
and CRC has long been recognized, there is not much known 
concerning the role Sg plays in the development of CRC. Some 
studies have suggested that Sg is merely a consequence of 
preferential colonization of the tumor environment [67], while 
others have suggested that Sg plays an etiological role in 
tumorigenesis [8, 66, 68]. However, some epidemiological 
studies provide hints at a possible active role of Sg in CRC 
development. First, the strong association of patients with S. 
bovis biotype I bacteremia/endocarditis with CRC is striking 
and much higher than that observed with other S. bovis 
biotypes [66]. It was also found that patients with S. bovis 
biotype I, in the absence of bacteremia/endocarditis, have a 
higher incidence of CRC and tumor tissues from these patients 
were more readily colonized [10, 66]. Additionally, patients 
with bacteremia/endocarditis due to S. bovis developed 
significantly more colonic neoplastic lesions in subsequent 
years (2 to 4 years) compared to patients with 
bacteremia/endocarditis due to enterococci. This suggests a 
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role of Sg in early stages of tumor development [69, 70]. 
Overall, despite the strong epidemiological evidence for an 
association between Sg and CRC, the role Sg plays in the 
development of CRC is unclear. 
Sg genomes. In general, Sg strains possess a single, 
circular chromosome of approximately 2.3 Mbps. Eleven strains 
have been sequenced to date with the majority of analytical 
data available for strains BAA-2069, UCN34, TX20005, and ATCC 
43143 [71-73]. Genomic analyses have shown a similar gene 
arrangement between the genomes of BAA-2069 and UCN34 and an 
87% commonality in open reading frames (ORFs). An 
extrachromosomal plasmid has been identified in BAA-2069, but 
not UCN34, TX20005, or ATCC 43143. This 20,765 base pair (bp) 
plasmid, pSGG1, confers tetracycline resistance and may also 
be important for conjugation. 
Sg strains demonstrate other notable features, including 
structural genes that encode capsules and bacterial pili. 
These particular structures are important for bacterial 
persistence within the host under certain conditions. For 
example, a 12-gene operon that encodes the extracellular 
capsule results in increased bacterial resistance to host 
innate immunity and mechanisms of bacterial clearing by 
complement and phagocytosis [74, 75]. 
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Further, Sg strain UCN34 also possesses three pilus 
operons. These pili have been shown to function as adhesins 
and bind collagens and mucins. Homologous sequences to these 
pili genes are also seen in TX20005 and ATCC 43143. Numerous 
studies demonstrate bacterial attachment to host tissues by 
pili as a first step in pathogenesis. Additionally, there are 
29 predicted LPXTG motif proteins in ATCC 43143, 21 in BAA-
2069, and 18 in UCN34. The predicted function of many of these 
is to aid in bacterial adherence.  
In addition to the genes that encode capsules or pili, Sg 
strains often express genes that result in the production of 
unique enzymes facilitating survival within the intestinal 
tract of the host. For example, Sg produces a tannase enzyme, 
which has the ability to degrade tannins (plant materials 
toxic to many bacteria) and to hydrolyze bile salts 
(conferring resistance to detergents). In addition to these 
enzymatic activities, Sg is predicted to encode 25 efflux 
proteins, critical in bacterial detoxification. All of these 
properties allow for survival of Sg in the gastrointestinal 
tract [71, 73]. Currently, there are no known Sg secreted 
toxins.  
The pili operon and gut colonization. Pili are 
filamentous structures that play an important role in 
bacterial adhesion in many pathogens. Genome sequencing of Sg 
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UCN34 found the presence of three pilus loci, pil1, pil2, and 
pil3 [73]. Earlier work by Danne, et al. showed that Pil1 
mediated Sg adherence to collagen in a rat model of 
experimental endocarditis [76]. More recently, Pil3 has been 
identified as an important mediator in colon colonization with 
specific regard to mucus attachment. The pil3 locus consists 
of genes encoding 2 structural pilin subunits (gallo_2040 and 
gallo_2039), a sortase C enzyme, a type 1 signal peptidase, 
and a small open reading frame of unknown function [77]. The 
two structural pilin subunits, Pil3A and Pil3B, are the 
adhesin and major pilin, respectively. Initial bioinformatics 
analysis of Pil3A was of particular interest in this study due 
to putative mucus-binding domains. Pil3 expression is 
regulated through a phase variation mechanism in which 
additions or deletions of an upstream GCAGA repeat results in 
transcriptional read through or termination [78]. A longer 
upstream repeat allows for transcription of the pil3 locus and 
subsequent Pil3 expression. This mechanism of Pil3 regulation 
results in heterogeneous expression of Pil3 on bacterial 
cells. Since Pil3 is heterogeneously expressed on UCN34 cells 
this study used a Pil3 overexpression strain and a Δpil3 
mutant to demonstrate the important role of Pil3 in its 
association with colon mucus in Sg colonic cell attachment. 
Currently, it is unclear if all Sg strains express Pil3, and 
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more specifically, pilin surface expression levels are 
unknown. 
 Sg pili have also been shown to be common antigens 
expressed in vivo, which could aid in the early detection of 
CRC. Boleji et al. identified 4 antibodies to pili that could 
serve as an assay for the detection of Sg in patients, with a 
sensitivity of 16-43% [79]. Butt et al. found Pil3B and Pil1 
to be most significantly associated with an increased risk of 
CRC [40]. Furthermore, when antibodies to these two pili 
proteins were detected simultaneously this strengthened the 
association. Gonzalez et al. identified 22kd and 30kd proteins 
that have a strong association with CRC, but the identity of 
these proteins has not been revealed [80]. It would be 
interesting to know if these are pilus proteins as well.   
Binding to extracellular matrix components. One of the 
first steps in bacterial pathogenesis is microbial attachment 
to host tissues. This attachment is often facilitated by a 
bacterial factor, such as a surface protein, that binds to 
specific host molecules or receptors on host tissues. Sg is 
known to colonize both the intestinal tract and heart valves. 
A study by Sillanpaa et al. evaluated 17 Sg clinical isolates 
from patients with endocarditis and their ability to bind to 
extracellular matrix (ECM) proteins [81]. Of these isolates, 
76% adhered to collagen type I, followed by 53% that adhered 
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to collagen type IV, 47% adhered to fibrinogen, and 35% 
adhered to collagen type V and fibronectin. There were three 
isolates that adhered to all ECM proteins investigated and 
three isolates that did not adhere to any ECM proteins. The Sg 
strains in this study were also analyzed by pulse-field 
electrophoresis and over 50% of the isolates were genetically 
diverse. Due to the diversity among strains and differences in 
Sg adherence, this suggests different Sg isolates express 
different surface proteins to colonize patients. This genetic 
diversity and the differences in Sg strain adherence to the 
various ECM components suggest that individual Sg isolates 
express different surface proteins with which the bacteria 
bind to host tissues. These differences in adherence also 
suggest that heterogeneous expression of bacterial surface 
adhesion factors may account for the disparate ECM binding 
results and that surface adhesin expression may be a highly 
regulated event. Vollmer et al. reported adherence of Sg to 
endothelial cells [82]. They also found that Sg adhered highly 
to collagen I, II, and IV, followed by fibrinogen, tenascin, 
and laminin. Interestingly, only 9 of the 23 isolates 
evaluated possessed Pil3, again suggesting other factors are 
involved in Sg adherence and colonization. 
Other factors that may be involved in the colonization of 
the gut. Several bacterial factors have been shown to mediate 
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Sg adherence. For example, Boleij et al. reported the role of 
histone-like protein A (HlpA) in mediating adherence to HCT116 
and HT29 colon cancer cell lines [83]. Another class of 
proteins called MSCRAMMS (Microbial Surface Components 
Recognizing Adhesive Matrix Molecules) are also known to 
promote bacterial adherence of Gram-positive bacteria to host 
tissues [84]. MSCRAMMs are proteins attached to the bacterial 
cell wall by the enzyme, sortase, which recognizes an LPXTG 
anchoring motif within the target MSCRAMM to mediate covalent 
attachment and bacterial surface expression of the adhesion. 
When Sillanpaa et al. analyzed Sg TX20005, they identified 11 
putative proteins with LPXTG motifs. Additional bioinformatics 
analysis predicted that these 11 proteins possessed binding 
domains to ECM components, such as collagen. Assays using 
recombinant protein of these binding domains demonstrated 
adherence to the ECM component, collagen. These data provide 
further evidence that pili are not the only factors on the 
surface of Sg strains mediating bacterial adherence [85].
 Not only is adherence important in Sg colonization, but 
the ability of Sg to grow in the colonic tumor environment. 
Boleij et al. also investigated the ability of Sg to grow in 
spent media from malignant colonocytes, which mimics the 
colonic tumor microenvironment [86]. Sg had a growth advantage 
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in comparison to other bacteria, suggesting the tumor 
environment provides a specialized niche for Sg growth.  
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Chapter 2: Sg promotes colorectal tumor development. 
INTRODUCTION 
Sg belongs to the SBSEC group, which also includes a 
number of closely related species such as S. pasteurianus 
(Sp), S. macedonicus (Sm), and S. infantarius (Sp) [1, 20]. 
Among the different species within SBSEC, Sg infection has the 
strongest association with CRC (~ 7 fold higher risk compared 
to infections caused by the other species), suggesting the 
existence of a Sg-specific mechanism(s) that promotes the 
association between the pathogen and CRC. Despite the well-
documented strong association between Sg and CRC, the role of 
Sg in CRC development, i.e. whether it drives colon 
tumorigenesis or merely colonizes the colon tumor environment, 
was unknown.   
Pertinent studies. Unpublished studies from our 
laboratory demonstrate that Sg promotes colon cancer cell 
proliferation in a manner requiring specific interactions 
between Sg and colon cancer cells. As these studies are highly 
pertinent, they are summarized below.  
1) Sg promotes colon cancer cell proliferation. The 
overall effect of Sg on cell growth and proliferation was 
examined using a variety of cell lines. Human colon cancer 
cell lines HCT116, HT29, LoVo, SW480, SW1116, normal human 
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colon epithelial cell lines FHC and CCD 841 CoN, human kidney 
epithelial cell HEK293 and human lung cancer cell line A549 
were co-cultured with Sg strains TX20005 and TX20030, and 
Lactococcus lactis MG1363 (used as a negative control 
bacterial strain). The number of viable cells was counted 
after 24 and 48 hours of incubation. We found that, in the 
presence of the Sg strains, HCT116, HT29 and LoVo had 
significantly more viable cells than the respective untreated 
or L. lactis- treated colon cancer cells (~ 50-60% more at 24 
hours and ~ 20-30% more at 48 hours) (Fig. 1a-1c). 
Interestingly, we did not observe any increase in cell numbers 
for the other cell lines tested including the colon cancer 
cell lines SW480 and SW1116 (Fig. 1d-1i). These results 
suggest that Sg strains TX20005 and TX20030 promote colon 
cancer cell growth in a cell context-dependent manner. 
Therefore, we refer to HT29, HCT116 and LoVo hereafter as 
“responsive” colon cancer cells, and the others as 
unresponsive cells. 
The increased viable cell numbers after co-culture with 
Sg could be due to increased proliferation, reduced apoptosis, 
or both. We therefore examined the effect of Sg on cell 
proliferation and apoptosis. Cells co-cultured with Sg or L. 
lactis were labeled with bromodeoxyuridine (BrdU) and analyzed 
by flow cytometry. Co-culture with Sg TX20005 resulted in ~1.6 
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Figure 1: Sg stimulates cell proliferation in responsive colon cancer cell 
lines. Human colon cancer cell lines HCT116 (A), HT29 (B), LoVo (C), SW480 
(D), and SW1116 (E), human lung cancer cell line A549 (F), human kidney 
epithelial cell line HEK293 (G), and normal human colon epithelial cell 
lines CCD841CoN (H) and FHC (I) were tested. Cells were seeded into the 
wells of 6-well plates at 1x104 cells per well and incubated for 12 hours. 
Stationary phase bacteria were washed with sterile phosphate buffered 
saline, pH 7.4 (PBS) and resuspended in the appropriate cell culture 
media. Bacterial suspension or media only were then added to the wells at 
1x102 cfu/well, and incubated for 24 or 48 hours. Cells were stained with 
trypan blue and counted in an automated cell counter. Data are presented 
as the mean ± SEM. Each experiment was done with duplicate wells and 
repeated at least three times. *, p < 0.05; **, p < 0.01, t test. 
Experiment performed by Ritesh Kumar, Ph.D. 
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- 2 and ~ 0.6 – 0.7 fold increase in the percentage of S phase 
cells in HCT116 and HT29 cells, respectively, compared to L. 
lactis treated cells or cells only control (Fig. 2a-2b). No 
significant changes in the percentage of S phase cells were 
observed in FHC cells following treatment with TX20005, as 
compared to untreated or L. lactis-treated FHC cells (Fig. 
2c). We further determined the level of proliferating cell 
nuclear antigen (PCNA), a marker for cell proliferation [87], 
in cells treated with Sg, L. lactis or cells only. The results 
showed that HCT116 and HT29 cells treated with TX20005 had 
significantly higher levels of PCNA compared to cells treated 
with L. lactis or cells only control (Fig. 2d-2i). No 
difference was observed in PCNA levels in FHC cells between 
the different treatment groups, as expected. These results 
indicate that Sg promotes cell proliferation in responsive 
cells. 
We next examined the effect of Sg on cell apoptosis in 
HCT116, HT29, and FHC cells co-cultured with TX20005, L. 
lactis, or media only. The cells were stained with anti-
Annexin V antibodies and propodium iodide followed by flow 
cytometry analysis. No significant difference was observed in 
the percentage of apoptotic cells between the different 
treatment groups in any of the cell lines (Fig. 2j-2l). To 
further confirm this, we compared the level of cleaved caspase 
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Figure 2: Sg promotes cell proliferation but does not affect apoptosis. 
HCT116, HT29, or FHC cells (~1x105/well) were incubated with L. lactis or 
TX20005 (~1x105/well) or media only for 12 hours.  Cells were pulsed with 
10 µM BrdU for 30 mins, incubated with anti-BrdU antibodies and secondary 
antibodies, and analyzed by flow cytometry (A - C).  The level of PCNA was 
determined by western blot assays using total cell lysates from cells co-
cultured with TX20005, L. lactis or media only. Representative images are 
shown (D - F). Band intensity was quantified using Image J, normalized to 
β-actin, and combined from at least three independent experiments (G – I). 
Apoptotic cells were detected by staining with PI and anti-Annexin V 
antibodies and secondary antibodies, followed by flow cytometry (j – l). 
Each experiment was done with duplicate wells and was repeated at least 
three times. *, p < 0.05; **, p < 0.01, t test. Experiment performed by 
Ritesh Kumar, Ph.D. 
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3 and observed no difference between the different treatment 
groups in any of the cell lines tested (Fig. 3). Taken 
together, these results indicate that Sg does not affect cell 
apoptosis, but promotes colon cancer cell proliferation in a 
cell context-dependent manner. 
2) The proliferation-promoting effect of Sg was Sg-
specific and depends on bacterial growth phase and direct 
contact between bacteria and responsive cells. We next 
examined the effect of an expanded panel of bacterial strains 
on HT29 and HCT116. The panel included Sg strains TX20005, 
TX20030 and TX20031, and strains of closely related species 
within the SBSEC - S. infantarius (TX20012), S. macedonicus 
(TX20026), and S. pasteurianus (TX20027). E. coli strain XL-1 
Blue and L. lactis were included as negative control bacteria. 
All three Sg strains significantly increased HT29 (Fig. 4a) 
and HCT116 (Fig. 4d) cell numbers whereas none of the other 
bacterial strains had any effect.  
 In the co-culture experiments described above, the 
bacteria added to the wells were from stationary phase 
cultures. We examined the effect of exponential phase cultures 
of TX20005, TX20030 and L. lactis on HT29 and HCT116 cells. In 
contrast to stationary phase bacteria, exponential phase 
TX20005 or TX20030 did not cause any significant increase in 
HT29 (Fig. 4b) or HCT116 (Fig. 4e) cell numbers compared to  
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Figure 3. Detection of cleaved caspase 3 in cells treated with S. 
gallolyticus. Approximately 1x105 cells were incubated with media only, L. 
lactis or TX20005 (~105 cfu) for 12 hrs in a 6 well plate. Whole cell 
lysates were prepared as described in the Methods and Materials section 
and analyzed by western blot assays. (A) HCT116; (B) HT29; (C) FHC. The 
experiment was repeated three times and representative images are shown. 
Experiment performed by Ritesh Kumar, Ph.D. 
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Figure 4: Promotion of cell proliferation requires Sg-specific factors and 
depends on bacterial growth phase and direct contact with CRC cells. A and 
D. Species closely related to Sg do not promote cell proliferation. 
Stationary phase bacteria were added to HT29 (A) and HCT116 (D) cells, co-
cultured for 24 hours and viable cell numbers enumerated. TX20005, TX20030 
and TX20031, Sg; TX20012, S. infantarius; TX20026, S. macedonicus; 
TX20027, S. pasteurianus. B and E. Promotion of cell proliferation 
requires stationary but not exponential phase Sg.  TX20005 bacteria 
harvested at exponential or stationary phase of growth were added to HT29 
(B) and HCT116 (E) cells and co-cultured with for 24 hours. Viable cell 
numbers were enumerated. E and F. Promotion of cell proliferation requires 
direct contact between Sg and responsive cells. Stationary phase TX20005 
bacteria were added to transwell inserts (0.4 µm pore) (TX20005-TW) or 
directly to cells and co-cultured with HT29 (E) and HCT116 (F) cells for 
24 and 48 hours. Data are presented as the mean ± SEM. Each experiment was 
done with duplicate wells and was repeated at least three times. *, p < 
0.05;**, p < 0.01, t test. Experiment performed by Ritesh Kumar, Ph.D. 
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the controls, suggesting that the ability of Sg to promote 
cell proliferation is growth phase-dependent.  
 We next examined whether secreted bacterial factors or 
bacterial metabolites in the culture supernatant were 
sufficient to promote colon cancer cell growth.  Supernatants 
from stationary phase cultures of TX20005, TX20030 and E. coli 
were collected and filtered to remove any residual bacteria. 
HT29 and HCT116 cells were cultured in media only or media 
supplemented with the culture supernatants.  The results 
showed that culture supernatants were insufficient to promote 
cell proliferation (Fig. 5). To distinguish between the 
possibilities that the proliferation-promoting effect of Sg 
required bacterial-attached factors, and that the 
factors/metabolites in the culture supernatants were unstable 
and required a continuous presence of live bacteria in the 
culture, we used a transwell system in which bacteria were 
cultured in inserts with permeable membranes of 0.4 µm pore 
size. This pore size allows the passage of secreted bacterial 
factors and metabolites but not bacteria. Culturing bacteria 
in transwells resulted in a complete loss of the 
proliferation-promoting effect of TX20005 on both HT29 and 
HCT116 cells   (Fig. 4c, Fig. 4f). Taken together, these 
results suggest that the proliferation-promoting effect of Sg  
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Figure 5. S. gallolyticus culture supernatant had no effect on cell 
proliferation. 1x104 HT29 (A) and HCT116 (B) cells were co-cultured with 
bacterial supernatant or 1x102 bacterial cells collected from stationary 
phase culture. Cells were then incubated for 24 hours and viable cells 
enumerated. Cell numbers are normalized to the untreated samples at 24 
hours. Data is presented as the mean ± SEM. Each experiment was performed 
with duplicate wells and repeated at least three times.*, p < 0.05; **, p 
< 0.01, t test. Experiment performed by Ritesh Kumar, Ph.D. 
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is dependent on Sg-specific factors, bacterial growth phase 
and direct contact between bacteria and responsive cells.  
3) Sg promotes cell proliferation in a β-catenin 
dependent manner. The Wnt/β-catenin signaling pathway 
regulates cell fate and proliferation and is a critical 
pathway in colon tumorigenesis [88-90]. We investigated the 
effect of Sg on β-catenin in responsive and unresponsive 
cells. For HCT116 and HT29 cells, co-culture with TX20005 led 
to a significantly elevated level of total β-catenin compared 
to cells co-cultured with L. lactis or no bacteria (Fig. 6a-
6d). In contrast,  no increase in β-catenin level was observed 
in unresponsive FHC, SW480 and SW1116  cells following Sg 
treatment (Fig. 6e-6g). Upon activation, β-catenin is 
translocated into the nuclei and triggers the enhanced 
expression of downstream targets, such as c-Myc[91]. We then 
examined the level of nuclear β-catenin. The results showed 
that HCT116 and HT29 cells co-cultured with TX20005 had 
significantly increased nuclear β-catenin compared to cells 
co-cultured with L. lactis or cells only (Fig. 6a-6d). No 
change in nuclear β-catenin was observed in FHC cells under 
the same experimental conditions (Fig. 6e and 6f). In 
accordance with this observation, the level of c-Myc in HCT116 
and HT29 was also significantly increased following treatment 
by TX20005 compared to that in the control groups (Fig. 6a- 
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Figure 6: Sg increases the level of β-catenin and c-Myc in HCT116 and HT29 
cells. Approximately 1x105 cells/well were incubated with bacteria (~105 
cfu/well) or media only for 12 hours in a 6 well plate. Whole cell or 
nuclear lysates were extracted and analyzed by western blot assays using 
specific antibodies. Representative images are shown (A, C, E and G).  
Band intensity was quantified using Image J, normalized to β-actin or lamin 
B first and then normalized to cells only control. Results combined from 
at least 3 experiments are shown (B, D and F). A and B, HCT116; C and D, 
HT29; E and F, FHC.  G. Sg does not increase β-catenin level in SW1116 or 
SW480 cells. Experiment performed by Ritesh Kumar, Ph.D. 
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6d). No difference in the level of c-Myc was observed in FHC 
cells, as expected (Fig. 6e and 6f). Taken together, these 
results suggest that treatment of responsive cells with Sg 
results in up-regulation of β-catenin and its oncogenic 
downstream targets. To determine the role of β-catenin in Sg-
mediated cell proliferation, β-catenin stable knockdown cells 
were generated using specific shRNA. Knockdown was confirmed 
using western blot assays (Fig. 7).  In co-culture 
experiments, β-catenin knockdown completely abolished the 
effect of Sg on cell proliferation, whereas HT29 cells 
transfected with a control shRNA showed a similar increase in 
cell numbers as untransfected cells (Fig.8a). To further 
confirm this, we used a β-catenin responsive transcription 
(CRT) inhibitor iCRT3, which disrupts β-catenin-TCF4 
interaction[92]. In the presence of iCRT3, TX20005 treatment 
of HT29 cells did not increase cell proliferation compared to 
the control groups (Fig. 8b). We next examined the effect of 
TX20005 on the level of c-Myc and PCNA in the presence of 
iCRT3. Treatment of HT29 cells with iCRT3 significantly 
reduced the effect of TX20005 on c-Myc and PCNA expression 
(Fig. 8c-8d). Taken together, these results indicate that 
promotion of cell proliferation by Sg is through up-regulation 
of β-catenin dependent signaling. 
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Figure 7: β-catenin expression in untransfected HT29 cells (lane 1), HT29 
cells transfected with control shRNA (lane 2), and HT29 cells transfected 
with a β-catenin specific shRNA,  as assessed by immunoblotting. Experiment 
performed by Ritesh Kumar, Ph.D. 
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Figure 8: Sg promotes cell proliferation in a β-catenin dependent manner. 
A. Knockdown of β-catenin abolished the effect of Sg. Untransfected HT29 
cells, β-catenin stable knockdown HT29 cells (HT29-B1) or HT29 cells 
transfected with a control shRNA (HT29-C1) were seeded into the wells of 
6-well plates at ~1x104 cells/well and incubated for 12 hours. Stationary 
phase bacteria were added to the wells at ~1x102 cfu/well, and incubated 
for 24 or 48 hours. Cells were stained with trypan blue and viable cells 
counted in an automated cell counter. B - D. Inhibition of β-catenin 
transcriptional activity by iCRT3 renders cells unresponsive to Sg.  
Stationary phase TX20005 or L. lactis bacteria resuspended in the 
appropriate cell culture media were added to the wells at ~1x102 cfu/well 
in the presence or absence of iCRT3, incubated for 24 hours and viable 
cells enumerated (B). Total cell lysates were prepared and subject to 
western blot assays to compare β-catenin, c-Myc and PCNA protein levels. 
Representative images are shown (C). Band intensity was quantified using 
Image J, normalized to β-actin first and then to the cells only control 
(D). Data in panels a, b and d are presented as the mean ± SEM. Each 
experiment was done with duplicate wells and was repeated at least three 
times. *, p < 0.05; **, p < 0.01, t test. Experiment performed by Ritesh 
Kumar, Ph.D. 
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These in vitro data using cultured human colon cancer cells 
indicate that Sg promotes colon cancer cell proliferation by 
activating β-catenin signaling, and the promotion requires 
stationary bacteria and direct contact between Sg and colon 
cancer cells. The Wnt/β-catenin signaling pathway is the most 
critical pathway in colon tumorigenesis [88-90]. The finding 
that Sg upregulates β-catenin is therefore highly pertinent. 
The key question now is whether Sg promotes tumorigenesis in 
vivo. 
In this study, the effect of Sg on tumor growth in a 
xenograft model was examined. In addition, an azoxymethane 
(AOM)-induced mouse model of CRC was used to examine the 
effect of Sg on colon tumorigenesis. The results showed that 
Sg treatment resulted in larger tumors in the xenograft model. 
Furthermore, in the AOM model, mice treated with Sg had 
significantly more macroscopic tumors, higher tumor burden, 
higher average dysplasia grade, and increased cell 
proliferation and β-catenin level in colon crypts compared to 
control mice. These results shed light on a tumor-promoting 
role of Sg and have important implications with respect to 
microbial contributions to CRC as well as clinical practices 
to combat CRC. 
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EXPERIMENTAL PROCEDURE:  
Bacterial strains and culture conditions. S. bovis group 
strains (Sg, S. pasteurianus, S. infantarius, S. macedonicus, 
provided by Barbara E. Murray, University of Texas Medical 
School, Houston, TX) [85], Lactococcus lactis MG1363 (provided 
by Timothy J. Foster, Trinity College Dublin, Ireland), and E. 
coli XL-1 Blue were grown at 37°C in brain-heart infusion 
(BHI) broth with shaking or on BHI agar (Difco Laboratories, 
Sparks, MD). 
Cell lines and growth conditions. Human colon cancer cell 
lines HCT116 and HT29 were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM, GIBCO, USA) supplemented with 10% fetal 
bovine serum (FBS) (GIBCO, USA).  
Adherence assay. This was performed following a procedure 
described previously with slight modifications [93]. Cells 
were seeded onto the wells of 24-well tissue culture plates at 
106 cells/well. Bacteria from a stationary phase or exponential 
phase culture were washed twice in PBS, resuspended in DMEM 
supplemented with 10% FBS, and added to the wells at a 
multiplicity of infection (MOI) of 10. The plates were 
incubated in a humidified incubation chamber at 37°C with 5% 
CO2 for 1 hour. Each well was washed three times with sterile 
PBS to remove unbound bacteria. To determine the number of 
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associated bacteria, cells were lysed with sterile PBS 
containing 0.025% Triton X-100 and dilution plated. All 
experiments were performed in triplicate and repeated at least 
three times. Adherence was expressed as a percentage of total 
bacteria added.  
Animal experiments. Animal studies were performed in 
accordance with protocols approved by the Institutional Animal 
Care and Use Committee at the Texas A&M Health Science Center, 
Institute of Biosciences and Technology. Mice were fed with 
standard ProLab IsoPro RMH3000 (LabDiet).  (1) Xenograft 
model. HCT116 cells (1 x 106) were incubated with TX20005 or 
L. lactis (MOI = 1) for 12 hours. The cells were immediately 
washed, trypsinized and mixed with Matrigel (Corning, MA) 
according to the manufacture’s instructions and subcutaneously 
injected (100 µl) into the dorsal flap of 5-week-old nude mice 
(Jackson Laboratory, Bar Harbor, ME). Three hours after the 
injection, mice were administered a broad-spectrum antibiotic 
imipenem (MSD) by intraperitoneal (i.p.) injection (150 mg/kg 
body weight). Tumor diameters were measured with a digital 
caliper, and tumor volume calculated using the formula: Volume 
= (d1xd1xd2)/2, with d1 being the larger dimension[94]. (2) 
AOM-induced mouse model of CRC. Eight-week old female A/J mice 
(Jackson Laboratory, Bar Harbor, ME) were treated with AOM (10 
mg/kg body weight) by i.p. injection once a week for 2 or 4 
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weeks. Mice were then given ampicillin (1g/L) in drinking 
water for one week and switched to antibiotic-free water 24 
hours prior to bacterial inoculation. Mice were orally gavaged 
with saline, TX20005 or L. lactis using a feeding needle (~ 1 
x 108 cfu/mouse) at a frequency of three times per week for 24 
weeks, or once a week for 12 weeks and were euthanized one 
week after the final gavage. One hour before sacrifice, mice 
received an i.p. injection of BrdU at 100 mg/kg body weight. 
Colons were removed by cutting from the rectal to the cecal 
end and opened longitudinally for visual evaluation. Tumor 
number was recorded and tumor size measured using a digital 
caliper. Tumor burden was calculated as the sum of all the 
tumor volumes of one mouse. Visual evaluation was carried out 
by two blinded observers. 
Histology and immunohistochemistry. At necropsy, colons 
from 3 randomly selected mice from each group were “Swiss 
rolled” from the rectal to the cecal end, fixed in Methcarn 
(60% methanol, 30% chloroform, and 10% glacial acetic acid), 
paraffin embedded, and cut into 5µm sections across. Every 10 
sections were stained with hematoxylin/eosin (H&E) and 
histological evaluation performed by a pathologist in a 
blinded fashion. Pathological scores were given using the 
following scale [95]: 0, no dysplasia; 1, mild dysplasia 
characterized by aberrant crypt foci (ACF), +0.5 for small 
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gastrointestinal neoplasia (GIN) or multiple ACF; 2, moderate 
dysplasia with GIN, +0.5 for multiple occurrences or small 
adenoma; 3, severe or high grade dysplasia restricted to 
mucosa; 3.5, adenocarcinoma (involvement through muscularis 
mucosa); 4, adenocarcinoma (through submucosa and into or 
through the muscularis propria). Inflammation was scored using 
the following scoring matrix [96]: 0, normal; 1 - </= 1 
multifocal mononuclear cell infiltrates in lamina propria 
accompanied by minimal epithelial hyperplasia and slight to no 
depletion of mucous from goblet cells; 2, involves more of 
intestine or more frequent, occasional small epithelial 
erosions, no submucosa involvement; 3, moderate inflammation 
plus submucosa neutrophils, crypt abscesses, ulcers; 4, most 
of colon; transmural; crowding of epithelial cells with 
elongated crypts, ulcers plus crypt abscesses [96].  
Proliferating crypt cells were detected by staining every 
10 sections with anti-BrdU antibodies and counting BrdU-
positive cells. A total of ~100 crypts were counted per mouse 
and the percentage of BrdU+ cells vs. total crypt epithelial 
cells counted was calculated. Apoptosis was determined by 
performing TUNEL assay on every 10 sections. Crypts were 
counted in the same manner as for BrdU+ cells. Sections were 
also stained for β-catenin. A Leica DM2000 LED microscope was 
used for imaging. Paraffin embedding, sectioning, 
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histochemistry and immunohistochemistry were performed by the 
Histology Core, Gulf Coast Digestive Diseases Center, Baylor 
College of Medicine, Houston, TX.  
Detection of Sg by qPCR. Fecal pellets were collected 
from mice at the end of 12-week gavage with TX20005. DNA was 
extracted using QIAamp Fast DNA Stool Mini Kit (Qiagen) 
following manufacturer’s instructions. PCR primers were 
designed using Sg-specific sequences (forward primer – 5’ 
TGACGTACGATTGATATCATCAAC 3’, reverse primer –
5’CGCTTAACACATTTTTAGCTAATACG 3’). qPCR was performed using 
Fast Plus EvaGreen qPCR Master Mix (Biotium) in a Viia 7 Real 
Time PCR System (Applied Biosystems) with the following 
cycling condition: 95°C for 10 minutes followed by 40 cycles 
at 95°C for 30 seconds and 60°C for 1 minute. ΔCT was 
normalized to the results from qPCR reactions using universal 
16S rRNA primers.  
Immunofluorescence detection of Sg in the mouse colon. 
Rabbit serum was raised against formalin killed TX20005 
(Rockland Immunochemicals). The antiserum and pre-bleed serum 
were tested against TX20005, S. infantarius (TX20012), S. 
macedonicus (TX20026), S. pasterianus (TX20027), E. coli XL-1 
Blue, and L. lactis MG 1363, to determine the specificity of 
the antibodies. The antiserum specifically recognized Sg not 
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other bacterial strains under the experimental conditions 
(Fig. S8).  Methcarn-fixed paraffin embedded colon sections (5 
µm) from mice treated twice with AOM and 24 weeks of oral 
gavage with bacteria were used to detect Sg using an optimized 
procedure. Briefly, sections were deparaffined with xylene and 
rehydrated in an ethanol gradient. The slides were incubated 
in a citrate buffer at 95°C for 15 min, cooled to room 
temperature (RT), rinsed with PBS and incubated in blocking 
buffer (PBS containing 1% Saponin and 20% BSA) for 30 min. The 
slides were then incubated with rabbit anti-Sg serum (1:250 
dilution) at 4°C overnight, washed with PBS, and incubated 
with donkey-anti-rabbit Alexa 594 (1:500 dilution in PBS) for 
1 hr at RT. The slides were washed again, stained with DAPI, 
mounted and examined in a DeltaVision Elite microscope.  
 Statistical analyses. Pairwise comparison was done using 
Student’s t-test. Pearson correlation analysis was performed 
to determine any correlation between Sg burden and tumor 
number and burden, respectively. Analyses were carried out 
using the Graphpad Prism 6 software. 
RESULTS: 
Sg adheres to both responsive and unresponsive cells. 
Studies from our lab showed that Sg was able to promote the 
proliferation of HT29 and HCT116 cells, but not lung cancer 
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cell line A549 or normal colon epithelial cell line CCD 841. 
Since direct contact between bacteria and cancer cells is 
required to promote cell proliferation, we investigated the 
ability of Sg to adhere to responsive and unresponsive cell 
lines. The results showed that both TX20005 and TX20030 
adhered to HCT116, HT29, and A549 cells at a similar level (~ 
20% of the initial inoculum) and adhered slightly higher to 
SW1116 and SW480 (~ 30% of the initial inoculum). Adherence to 
CCD 841 CoN colonic epithelial cells was significantly lower 
than to the cancer cell lines (~15% of the initial inoculum) 
(Fig. 9). Together these results showed that the effects of Sg 
on cell proliferation were not in direct concordance with the 
ability of the bacteria to adhere to the cultured cell lines.  
Exponential and stationary phase bacteria were also 
evaluated for their adherence to both HCT116 and HT29 cell 
lines. Stationary phase Sg strains adhered significantly more 
to these cell lines than exponential phase Sg strains (Fig. 
10). These results show a similar effect as seen with 
exponential and stationary phase bacteria in our cell 
proliferation co-culture experiments, with stationary phase 
bacteria playing the important role in promoting cell 
proliferation. These results indicate the importance of 
stationary phase bacteria in both adherence and cell 
proliferation.   
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Figure 9. Adherence of S. gallolyticus to different cell lines. Stationary 
phase culture TX20005 and TX20030 were washed twice in PBS, resuspended in 
DMEM supplemented with 10% FBS, and added to the wells containing 
different cells at a multiplicity of infection (MOI) of 10, as described 
in the Methods and Materials section. The plates were incubated in a 
humidified incubation chamber at 37°C with 5% CO2 for 1 hr. Each well was 
washed three times with PBS to remove unbound bacteria. To determine the 
number of adhered bacteria, cells were lysed with sterile PBS containing 
0.025% Triton X-100 and dilution plated. All experiments were performed in 
triplicate wells and repeated at least three times. Adherence was 
expressed as the percentage of adhered bacteria vs. total bacteria added. 
*, p < 0.05; **, p < 0.01; t test. Experiment performed by Ritesh Kumar, 
Ph.D. 
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Figure 10. Adherence of S. gallolyticus and closely related strains to 
HCT116 cells. Stationary phase and exponential phase culture of TX20005, 
TX20030, and TX20031 were washed twice in PBS, resuspended in DMEM 
supplemented with 10% FBS, and added to the wells containing HCT116 cells 
at a multiplicity of infection (MOI) of 10, as described in the Methods 
and Materials section. The plates were incubated in a humidified 
incubation chamber at 37°C with 5% CO2 for 1 hr. Each well was washed three 
times with PBS to remove unbound bacteria. To determine the number of 
adhered bacteria, cells were lysed with sterile PBS containing 0.025% 
Triton X-100 and dilution plated. All experiments were performed in 
triplicate wells and repeated at least three times. Adherence was 
expressed as the percentage of adhered bacteria vs. total bacteria added. 
*, p < 0.05; **, p < 0.01; t test. 
 
 
 
 
 
TX
20
00
5-
S
TX
20
00
5-
E
TX
20
03
0-
S
TX
20
03
0-
E
TX
20
03
1-
S
TX
20
03
1-
E
0
20
40
60
Ad
he
re
nc
e 
(%
) ****
**** ****
TX
20
00
5-
S
TX
20
00
5-
E
TX
20
03
0-
S
TX
20
03
0-
E
TX
20
03
1-
S
TX
20
03
1-
E
TX
20
00
8-
S
TX
20
00
8-
E
TX
20
02
7-
S
TX
20
02
7-
E
0
20
40
60
Ad
he
re
nc
e 
(%
) Stationary
Exponential
****
****
****
	 58	
Sg promotes tumor growth in a xenograft model. HCT116 
cells treated with TX20005 or L. lactis were injected into 
nude mice and tumor growth was monitored (Fig. 11). Starting 
from day 13, TX20005-treated cells formed significantly larger 
tumors than L. lactis-treated cells.  Expression of β-catenin, 
c-Myc and PCNA was analyzed in tumors obtained at day 21 
(Fig.11b-11c). A significant increase in the levels of β-
catenin, c-Myc and PCNA were observed in tumors from TX20005-
treated cells compared to those from L. lactis-treated cells. 
These results indicate that TX20005 treatment promoted tumor 
growth in the xenograft model. 
Sg promotes colon tumor development in an AOM-induced 
mouse model of CRC. To further evaluate the role of Sg in 
tumor development, we used an AOM-induced mouse model of CRC. 
This model is commonly used to represent sporadic CRC. Mice 
were treated with 2 doses of AOM followed by antibiotic 
treatment for a week and then orally gavaged with TX20005, L. 
lactis or saline for 24 weeks. Colons were harvested for 
visual examination for macroscopic tumors (Fig. 12). Overall, 
most of the tumors were found in the distal portion of the 
colon. We observed that Sg-treated mice had more tumors per 
mouse compared to the saline control (p = 0.03) and L. lactis-
treated mice although the difference with the latter group was 
not statistically significant (p = 0.08) (Fig. 13a). In  
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Figure 11: Sg treatment promotes tumor growth in a xenograft model. A. Sg-
treated cells developed larger tumors in nude mice. ~ 1x 105 HCT116 cells 
were treated with TX20005 or L. lactis, mixed with Matrigel and injected 
into the dorsal flap of nude mice (n=5/group) as described in the Methods 
and Materials section. Tumor size was measured during the indicated time 
period with a digital caliper. B-C. Sg-treated xenografts had higher 
levels of β-catenin, c-Myc and PCNA compared to L. lactis-treated ones.  
Three tumors were randomly selected from each group and collected on day 
21. Protein extracts were analyzed by western blot assays (B). Protein 
level was normalized to β-actin first and then to L. lactis-treated 
controls (C). Data are presented as the mean ± SEM. *, p < 0.05; **, p < 
0.01, t test.  
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Figure 12. At necropsy, mouse colons were removed and cut from the distal 
to the proximal end in a longitudinal direction. Tumors were visually 
evaluated for tumor number and size. Representative images from saline 
treated mice (A) and TX20005 treated mice (B) are shown. 
 
 
 
 
 
 
 
 
 
A. 
B. 
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Figure 13: Sg promotes colon tumor development in an AOM-induced mouse 
model of CRC. A-D. A/J mice were administered 2 weekly i.p. injections of 
AOM, followed by treatment with Amp (1g/L) in drinking water for 1 week 
and then oral gavage of bacteria or saline for 24 weeks. Colons were 
visually examined for the number of tumors (A) and tumor burden (B) was 
calculated as described in the Methods and Materials section. H&E stained 
colon sections were evaluated for dysplasia (C) according to the scale 
described in the Methods and Materials section. An image from the TX20005-
treated group with a dysplasia grade of 3.5 is shown. n = 5 for saline, n 
= 7 for L. lactis and TX20005, respectively. *, p < 0.05; **, p < 0.01; t 
test. 
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addition, tumor burden in Sg-treated mice was significantly 
higher compared to both the saline and L. lactis control 
groups (Fig. 13b).  
H&E stained colon sections were evaluated. Colons from 
Sg-treated mice showed a significantly higher average 
dysplasia grade compared to those from L. lactis-treated or 
saline control mice (Fig. 13c). Adenocarcinomas were observed 
in Sg-treated mice but not in the control groups (Fig. 13d).  
We further tested the effect of Sg on tumor development 
using a different shorter procedure, in which mice were 
treated with four doses of AOM and gavaged with bacteria for 
12 weeks. Similar to the results from the first longer 
procedure, a significant increase in tumor numbers was 
observed in Sg-treated mice compared to the saline control 
(Fig. 14a). When compared to the L. lactis group, mice gavaged 
with TX20005 also had more tumors; however, the difference was 
not statistically significant (p = 0.08). Tumor burden also 
displayed a similar trend as that observed in the longer 
procedure, in which Sg-treated mice had a higher average tumor 
burden than the other two groups (Fig. 14b). In the shorter 
procedure, however, the difference was not statistically 
significant, perhaps due to reduced duration, less bacterial 
gavage or more AOM injections in this second procedure. 
Overall, results from the two procedures show a consistent  
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Figure 14. S. gallolyticus promotes colon tumor development in an AOM-
induced mouse model of CRC. A/J mice were administered with 4 weekly i.p. 
injections of AOM, followed by treatment with Amp (1g/L) in drinking water 
for 1 week and oral gavage of L. lactis (n = 17), TX20005 (n = 19) or 
saline (n = 17) for 12 weeks. Colons were visually examined to determine 
tumor number (A). Tumor size was measured and tumor burden (B) was 
calculated as described in the Methods and Materials section. Data shown 
is mean ± SEM. *, p < 0.05, t test. 
 
 
 
 
 
 
 
	 64	
trend towards Sg acting as a promotional agent for tumor 
development in the mouse colon. 
Sg promotes colonic crypt cell proliferation in vivo. We 
next examined cell proliferation and apoptosis in mouse 
colonic crypt cells by determining the percentage of 
proliferating cells or apoptotic cells per crypt. Mouse colons 
were sectioned consecutively and every 10th section was counted 
for cells that stained positive for BrdU (proliferation 
marker) or cells that stained positive for TUNEL (apoptotic 
marker). Approximately 100 crypts were counted per mouse. Sg-
treated animals had a significantly higher percentage of 
proliferating cells (BrdU+) in the colonic crypts compared to 
L. lactis- or saline-treated control groups (Fig. 15 a-b). In 
contrast, we did not observe any significant difference in the 
percentage of apoptotic cells between the different treatment 
groups as determined by TUNEL assays (Fig. 16 a-b). In 
addition, Sg-treated mice had higher levels of β-catenin in 
the colon epithelium as compared to L. lactis-treated or 
saline controls (Fig. 17a). These results are consistent with 
the observations from our in vitro cell culture assays.  
Sg does not induce strong inflammatory responses. A panel 
of cytokines (TNFa, IL-6, COX-2, IL-1B, IL-10, IL-17, and IL-
23) were selected for their role in inflammation and evaluated 
in the normal and tumor tissues of mice. There was no  
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Figure 15: Sg promotes colon tumor development in an AOM-induced mouse 
model of CRC. A/J mice were administered 2 weekly i.p. injections of AOM, 
followed by treatment with Amp (1g/L) in drinking water for 1 week and 
then oral gavage of bacteria or saline for 24 weeks. Proliferating cells 
were determined by staining colon sections for BrdU incorporation (A and 
B). n = 5 for saline, n = 7 for L. lactis and TX20005, respectively. *, p 
< 0.05; **, p < 0.01; t test. 
 
 
A. 	
	
B. 	  
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Figure 16. TUNEL assay of colon sections from mice treated with AOM and 
bacteria. A/J mice were administered with 2 weekly i.p. injections of AOM, 
followed by treatment with Amp (1g/L) in drinking water for 1 week and 
oral gavage of saline, L. lactis, or TX20005 for 24 weeks. Methcarn-fixed 
colon sections (5 µm) were subject to TUNEL assays to detect apoptotic 
cells (A and B). (n = 3/group). *, p < 0.05; **, p < 0.01; t test. 
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Figure 17. Sg increases B-catenin levels, but does not promote 
inflammation in a mouse model.  Colon sections were also stained for β-
catenin (A) H&E stained colon sections were also evaluated for 
inflammation according to the scale described in the Methods and Materials 
section and average inflammation score for each treatment group is shown 
(B). n = 5 for saline, n = 7 for L. lactis and TX20005, respectively. *, p 
< 0.05; **, p < 0.01; t test. 
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significant change in these cytokines between Sg- and L. 
lactis- treated groups in either the 2 AOM (Fig. 18) or 4 AOM 
group (Fig. 19), indicating that Sg does not induce a strong 
inflammatory response.   
Inflammation in the colon of mice was also scored by 
evaluating the H&E stained slides. Both Sg- and L. lactis-
treated groups displayed significantly higher average 
inflammation scores compared to the saline group.  However, 
overall inflammation in these groups was mild, with few areas 
of lymphocyte infiltration and minimal epithelial hyperplasia. 
There was no apparent difference between the Sg- and L. 
lactis-treated groups (Fig. 17b), suggesting that in terms of 
inducing inflammation Sg and L. lactis have a similar effect.  
Sg abundance in the colon correlates with tumor 
multiplicity and tumor burden. To determine whether the 
abundance of TX20005 in the colon correlates with tumor number 
or burden in the mice, we collected fecal material from mice 
at the end of the 12-week gavage experiment. Relative 
abundance of Sg was determined by qPCR using Sg specific 
primers. The development of the qPCR procedure is described in 
more detail in Chapter 3. We observed statistically 
significant correlations between the relative abundance of 
TX20005, tumor number (Fig. 20a, Pearson’s r = -0.6548, p =  
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Figure 18. Sg does not induce strong inflammatory responses. At necropsy, 
tumor and adjacent normal tissues were collected from mice in the two AOM 
treatment group and immediately stored in liquid nitrogen. Tissues were 
then processed for RNA using the All-Prep DNA/RNA/Protein Mini kit 
(Qiagen) and converted to cDNA using the Transcriptor First Strand cDNA 
Synthesis Kit (Roche). PCR primers to TNFa, IL-6, COX-2, IL-10, IL-17, and 
IL-23 were used in a qPCR reaction using SYBR Green qPCR Master Mix 
(Roche) in a Viia 7 Real Time PCR System (Applied Biosystems). The 
following cycle conditions were used: 95°C for 10 minutes followed by 40 
cycles at 95°C for 30 seconds and 60°C for 1 minute. ΔCT was normalized to 
the results from the qPCR reactions using β-actin primers.  
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Figure 19. Sg does not induce strong inflammatory responses. At necropsy, 
tumor and adjacent normal tissues were collected from mice in the four AOM 
treatment group and immediately stored in liquid nitrogen. Tissues were 
then processed for RNA using the All-Prep DNA/RNA/Protein Mini kit 
(Qiagen) and converted to cDNA using the Transcriptor First Strand cDNA 
Synthesis Kit (Roche). PCR primers to TNFa, IL-6, COX-2, IL-10, IL-17, and 
IL-23 were used in a qPCR reaction using SYBR Green qPCR Master Mix 
(Roche) in a Viia 7 Real Time PCR System (Applied Biosystems). The 
following cycle conditions were used: 95°C for 10 minutes followed by 40 
cycles at 95°C for 30 seconds and 60°C for 1 minute. ΔCT was normalized to 
the results from the qPCR reactions using β-actin primers.  
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Figure 20. Correlation of bacterial burden with tumor number and burden. A 
and B.  Fecal pellets were collected from mice at the end of the 12-week 
oral gavage of TX20005 (14 mice). DNA was extracted and analyzed by qPCR 
to determine the relative abundance of TX20005 as described in the Methods 
and Materials section. Pearson correlation analysis was performed between 
-ΔCT and tumor number (A) and burden (B), respectively. C and D. Detection 
of Sg in colon tumor tissues. Methcarn-fixed paraffin embedded colon 
sections (5 µm) from mice treated twice with AOM and 24 weeks of oral 
gavage with saline (C) or TX20005 (D) were incubated with anti-TX20005 
antiserum and secondary antibodies as described in the Methods and 
Materials section. Nuclei were stained with DAPI. 
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0.0111), and tumor burden (Fig. 20b, Pearson’s r = -0.5404, p 
= 0.0460), respectively, suggesting a dose effect of Sg.  
Sg abundance in tumor vs. normal tissues. To evaluate the 
association of Sg with tumor vs. normal tissues in TX20005 
treated mice, we collected tumor and adjacent normal tissues 
from mouse colons. Relative abundance in these tissues was 
determined by qPCR. We observed a statistically significant 
difference between bacterial burden in tumor tissues in 
comparison to normal tissues (Fig. 21). This suggests a 
preferential association of Sg with tumor tissues. 
Immunofluorescence detection of Sg within tumor tissues 
in the mouse colon. Rabbit serum against formalin-killed 
TX20005 was raised. The specificity of the antiserum for two 
rabbits was tested against a panel of different bacteria. I 
tested strains of closely related species in SBSEC including 
S. infantarius, S. macedonicus, and S. pasteurianus. I also 
included Enterococcus faecalis strain V583, E. coli XL1-Blue 
and L. lactis. Antiserum was specific against Sg in the first 
rabbit (Fig. 22), however, the antiserum from the second 
rabbit showed non-specific binding to control strains (Fig. 
23). Antiserum from the rabbit producing Sg specific 
antibodies was used in subsequent experiments. 
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Figure 21. Sg abundance in tumor vs. normal tissues. Tumors and adjacent 
normal tissues were collected from mice at necropsy. DNA extraction and 
qPCR were performed as described in the Materials and Methods section to 
determine abundance of TX20005. Bacterial burden is expressed as CFU per 
100ng of DNA extracted from tissues. *, p < 0.05; **, p < 0.01; t test. 
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Figure 22. Specificity of rabbit 1 anti-Sg serum. Bacteria were attached 
to poly-L-lysine coated coverslips, fixed with 2% paraformaldehyde, 
blocked with PBS containing 5% goat serum, and incubated with rabbit 1 
anti-TX20005 serum (1:250) or pre-bleed serum (1:250), followed by donkey 
anti-rabbit Alexa Fluor (1:1000).  
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Figure 23. Specificity of rabbit 2 anti-Sg serum. Bacteria were attached 
to poly-L-lysine coated coverslips, fixed with 2% paraformaldehyde, 
blocked with PBS containing 5% goat serum, and incubated with rabbit 2 
anti-TX20005 serum (1:250) or pre-bleed serum (1:250), followed by donkey 
anti-rabbit Alexa Fluor (1:1000). 
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Antiserum was then used to stain methcarn-fixed mouse 
colon sections. In colon sections, we observed positive 
staining in Sg-treated mice but not in the saline control 
group (Fig.  20c and 20d), further indicating that the 
antiserum was specific. Sg bacteria were found within tumor 
tissues. The presence of Sg around normal-looking crypts was 
observed only occasionally, suggesting a preferential 
association of Sg with tumor tissues. 
DISCUSSION: 
 CRC is the second to third most common cancer and a 
leading cause of cancer death in the world. Annually, over a 
million people are diagnosed with CRC and ~700,000 die due to 
CRC [30]. In recent years, the role of microbial agents in CRC 
development has gained increasing recognition, raising hope 
that we may be able to exploit microbes to improve CRC 
diagnosis, prevention and treatment. To achieve this goal, a 
clear understanding of how precisely microbes exert their 
influence on tumor development is important. Sg has long been 
known to display a strong association with CRC, and yet 
virtually nothing was known about the nature of this 
association or the molecular mechanism underlying the 
association. The results described in this study provide 
exciting new insights into a tumor-promoting role of Sg that 
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is dependent on cell context, specific bacterial factors, 
direct contact with colon cancer cells, and β-catenin.  
In cell-based assays carried out in our lab, Sg increased 
cell proliferation without altering apoptosis, whereas 
bacterial species closely related to Sg failed to recapitulate 
these effects in vitro, suggesting Sg-specific factors are 
involved. This finding is consistent with previous clinical 
observations that among the closely related species in the S. 
bovis group, Sg displays a particularly strong association 
with CRC. The results also show that promotion of cell 
proliferation by Sg depends on bacterial growth phase and 
direct contact between the bacteria and responsive colon 
cancer cells, whereas secreted bacterial factors or soluble 
metabolites had no apparent effect on cell proliferation as 
demonstrated by the results from bacterial culture 
supernatants and transwell assays. These results suggest that 
the Sg factor(s) responsible for mediating the promotion of 
cell proliferation is surface associated and up-regulated in 
bacterial stationary phase and that promotion of cell 
proliferation is likely mediated by interactions between the 
Sg surface factor and specific cell surface receptor(s). 
Further studies are needed to characterize the nature of these 
cell surface interactions.  
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 Several lines of evidence indicating that Sg promotes 
cell proliferation through β-catenin. Sg-treated responsive 
cells had significantly increased levels of total and nuclear 
β-catenin, c-Myc and PCNA compared to L. lactis-treated cells 
or cells only control. Sg did not increase β-catenin level in 
unresponsive cells. Furthermore, knockdown of β-catenin in 
responsive cells by shRNA or inhibition of its transcriptional 
activity by a specific inhibitor abolished Sg’s effect on cell 
proliferation, c-Myc and PCNA. The Wnt/β-catenin signaling 
pathway regulates cell proliferation and cell fate. 
Dysregulation of this pathway plays a central role in the 
development of CRC [97-101]. It is highly pertinent, 
therefore, that Sg also targets this critical pathway in the 
etiology of CRC. Studies on other tumor-promoting bacteria 
indicate that diverse strategies are used to influence β-
catenin signaling. For example, Fusobacterium nucleatum 
modulates β-catenin signaling by binding to E-cadherin through 
its FadA adhesin [50]. Bacteroides fragilis secretes a zinc-
dependent metalloprotease toxin that cleaves E-cadherin, 
leading to nuclear translocation of β-catenin, increased c-Myc 
expression and cell proliferation [102]. Helicobacter pylori, 
which is an important cause for gastric cancer, activates β-
catenin signaling in multiple ways including affecting the 
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expression of Wnt ligands [36], activating Wnt receptors [35], 
suppressing GSK3β [34, 37], interfering with β-catenin/TCF4 
complex by down regulating the gastric tumor suppressor Runx3 
[103-105], and interacting with E-cadherin to disrupt the E-
cadherin/β-catenin complex [33]. In addition, there have been 
numerous studies in recent years linking microRNA (miRNA) 
dysregulation to CRC (recent reviews [106-110]). Evidence 
indicates that microbes (e.g., H. pylori, Citrobacter 
rodentium, and human papillomavirus (HPV)) can regulate β-
catenin signaling and cell proliferation by affecting certain 
miRNAs [111-113].  
In the case of Sg, all five of the colon cancer cell 
lines we tested contain mutations in the Wnt/β-catenin 
signaling pathway; HT29, LoVo, SW480 and SW1116 have mutations 
in APC whereas HCT116 contains a mutated version of β-catenin 
that results in increased protein stability [114, 115]. Sg 
further increases β-catenin level in HT29, HCT116, and LoVo, 
but not in SW480 and SW1116 cells. It is possible that Sg up-
regulates β-catenin at a more upstream level or by affecting 
factors outside the canonical Wnt/β-catenin signaling pathway. 
The fact that TX20005 adheres to unresponsive colon cancer 
cells as well as, or even better than, responsive cells 
suggests that the differential effects of Sg on responsive and 
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unresponsive cells are not due to any difference in the amount 
of bacteria adhering to these cells. Rather, whether or how 
the signal is transduced from the cell surface where Sg is 
attached is likely to be responsible for the difference. It is 
also possible that Sg adheres to different receptors on 
responsive and unresponsive cells. Overall, our results 
suggest that the effect of Sg depends on specific cell 
context. This implies that not everyone colonized by Sg may be 
equally affected; some individuals with certain genetic or 
epigenetic makeup may be more susceptible to the tumor-
promoting effect of Sg than others. Identifying host factors 
that render cells responsive to Sg will be important.  
The results from mouse models suggest that Sg promotes 
tumor development. Sg-treated cells developed larger tumors in 
the mouse xenograft model than cells treated with control 
bacteria. Higher levels of β-catenin, c-Myc and PCNA were also 
observed in Sg-treated xenografts compared to L. lactis-
treated ones.  In the AOM model, mice treated with Sg had more 
tumors and higher tumor burden compared to L. lactis or 
saline-treated mice. This was confirmed using two different 
experimental procedures. In addition, Sg-treated mice had a 
higher percentage of proliferating cells and stronger β-
catenin staining in colonic crypts compared to the control 
groups. Apoptosis in colon epithelial cells of Sg-treated mice 
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was similar to that in L. lactis-treated mice. These findings 
are consistent with the results from cell culture assays. 
Furthermore, a significant correlation was observed between Sg 
bacterial burden in the mouse colon and tumor number and 
burden, respectively, suggesting a dose effect. Finally, Sg 
bacteria were detected within tumor tissues; consistent with 
the in vitro finding that direct contact between Sg and cancer 
cells is important. The observation that Sg and L. lactis 
induced similar levels of inflammatory responses suggests that 
Sg-induced immune responses may not play a major role in Sg-
mediated tumor promotion. However, this does not exclude the 
possibility that Sg may induce specific types of immune 
reactions that favor tumor development. In addition, the role 
of microbiota in Sg-mediated tumor promotion remains unclear. 
The results here suggest a direct effect of Sg on colon 
epithelial cells. However, whether Sg functions in concert 
with other microbial agents in the gut or elicits specific 
responses when mixed with certain other microbes is unknown. 
Further studies are needed to clarify these issues. Overall, 
the results presented here support a model in which an 
increase in colon epithelial cell proliferation through up-
regulation of β-catenin by Sg is an important mechanism for 
Sg-mediated tumor promotion.  
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In summary, this is the first report demonstrating a tumor-
promoting role of Sg, an organism that has long been known to 
have a strong association with CRC. The findings here have 
important clinical implications. Going forward, identifying 
the Sg factor(s) responsible for promoting cell proliferation 
and tumor development, and host factors that render cells 
responsive to Sg, will be important for understanding how Sg 
functions as a tumor-promoting agent and for developing 
optimized strategies to fight CRC by taking both bacterial and 
host factors into consideration.  
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Chapter 3: Prevalence of Sg in human patient samples. 
INTRODUCTION:  
Within the S. bovis group Sg has the strongest 
association with CRC (~7 fold higher risk compared to 
infections caused by other S. bovis species) [10], suggesting 
an Sg-specific mechanism in the Sg-CRC association. It has 
been reported that 25 to 80% of patients with S. bovis 
bacteremia and 18 to 62% of patients with S. bovis 
endocarditis have CRC [11, 69, 116-120]. This wide range of 
association frequencies is most likely due to the lack of 
differentiation of Sg from other species within the S. bovis 
group, especially in earlier studies. In addition, a recent 
study followed patients with endocarditis due to Sg or 
Enterococcus spp. for an average of ~5.5 years and found that 
a significantly higher percentage of Sg endocarditis patients 
developed a new colonic neoplasm during the follow-up period, 
compared to enterococcal endocarditis patients (45.2% vs. 21%, 
p = 0.01) [121].  
A few studies have investigated the association between 
patients with S. bovis endocarditis and the different stages 
of CRC. Hoen et al. reported that 46.9% of patients with S. 
bovis endocarditis had adenomas, while 9.4% of patients had 
carcinomas, indicating an association with early colonic 
lesions [122]. A study by Abdulamir et al. found that Sg 
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selectively associates with the most aggressive polyps in the 
large intestine, and villous or tubulovillous adenomas [8]. 
Since colon cancer progresses from adenomas to carcinomas 
through genetic mutations, the association between Sg and 
adenomatous polyps seems to have significance and could 
indicate a promoter role of S. bovis in polyp progression. 
Compared to the well-documented association between Sg 
infection and CRC, the prevalence of Sg in CRC patients is 
relatively poorly defined. While previous studies approximate 
that 2.5-15% of the normal population is colonized with Sg, 
there is limited data documenting the prevalence of Sg in CRC 
patients [123, 124]. A recent study by Abdulamir et al. 
evaluated the presence of Sg in tumor tissues of CRC patients 
with or without a history of bacteremia within the last 2 
years through the use of conventional PCR and in situ 
hybridization (ISH) [66]. Their group detected Sg in 48.7% 
(PCR) and 46.1% (ISH) of patients with a history of bacteremia 
and 32.7% (PCR) and 28.8% (ISH) of patients without a history 
of bacteremia. This was significantly higher than the 4% (PCR) 
and 2% (ISH) of healthy patients that were positive for Sg. 
They also used absolute quantitative PCR to calculate the copy 
number of Sg DNA in these tissues. They found that patients 
with a history of bacteremia were more highly colonized than 
patients without a history of bacteremia and both CRC subsets 
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were significantly more colonized than normal control 
patients. This suggests that some CRC patients are “silently” 
infected with Sg, without concomitant Sg bacteremia or 
endocarditis. Additionally, a recent prospective study on 203 
colonoscopy patients found a clear relationship between 
positivity for S. bovis in the colonic suction fluid and 
presence of malignant tumors and large polyps in the colon 
[65]. Specifically, all 17 malignant tumors diagnosed in this 
cohort were S. bovis positive. Due to this strong clinical 
association, it is recommended that patients with Sg 
infections undergo colonic evaluation.  
In this study, we surveyed resected tumor and matched 
normal colon tissues from CRC patients and analyzed for the 
presence of Sg. We demonstrated that Sg is present in the 
majority of CRC patients and is more abundant in tumor tissues 
than in normal tissues from CRC patients. In addition, we 
evaluated the presence of another S. bovis, non-Sg strain and 
were only able to detect this strain in a small proportion of 
patients, indicating the specific association of Sg with CRC. 
EXPERIMENTAL PROCEDURE: 
Patient characteristics. Patient samples were provided by 
Dr. Scott Kopetz, Department of Medical Gastrointestinal 
Oncology, University of Texas M. D. Anderson Cancer Center, 
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Houston, TX.	Patient identifiers (privileged health information 
- PHI) were anonymized. Summary patient information was 
provided by members of the Kopetz lab and can be seen in Table 
2. 
Bacterial strains and culture conditions. S. bovis group 
strains (Sg, S. pasteurianus, S. infantarius, S. macedonicus, 
provided by Barbara E. Murray, University of Texas Medical 
School, Houston, TX) [85], Lactococcus lactis MG1363 (provided 
by Timothy J. Foster, Trinity College Dublin, Ireland), and E. 
coli XL-1 Blue were grown at 37°C in brain-heart infusion 
(BHI) broth with shaking or on BHI agar (Difco Laboratories, 
Sparks, MD). 
Identification of S. gallolyticus by qPCR. The genome 
sequences of three Sg strains (NC_015215.1, NC_013798.1 and 
NC_017576.1) were compared to those of closely related species 
in the S. bovis group (S. pasteurianus, S. infantarius and S. 
macedonicus) to identify Sg unique sequences, which were then 
used to design Sg-specific primers (forward primer – 5’ 
TGACGTACGATTGATATCATCAAC 3’, reverse primer –
5’CGCTTAACACATTTTTAGCTAATACG 3’). The primers were tested on a 
panel of Sg and non-Sg strains using conventional PCR to 
determine their specificity. One pair of primers that 
correctly amplified from all the Sg strains and none of the  
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Table 2: Patient characteristics. 
Characteristic  
Age at surgery, mean (SEM) 62.5 
Sex  
   Male  88 
   Female 58 
Tumor Stage  
   II 59 
   III 53 
   IV 5 
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non-Sg strains were chosen. qPCR was performed using Fast Plus 
EvaGreen qPCR Master Mix (Biotium) in a Viia 7 Real Time PCR 
System (Applied Biosystems) with the following cycling 
condition: 95°C for 10 minutes followed by 40 cycles at 95°C 
for 30 seconds and 60°C for 1 minute. ΔCT was normalized to 
the results from qPCR reactions using universal 16S rRNA 
primers. S. pasteurianus (Sp) specific primers (forward 
primer-ATGGATAGTCATAGAATTGA reverse primer-
GGACAATGCCCTCATCTAGC) were developed following the same 
strategy as described for Sg primers. The primers were tested 
on a panel of Sp and non-Sp strains and Sp specific primers 
were chosen.  
RESULTS: 
Establishing a protocol for specific detection of Sg in 
colon tissues. Sg-specific primers targeting Sg-unique 
sequences were designed and tested against a panel of 6 Sg 
strains and 4 strains of closely related species (S. 
infantarius, S. macedonicus, and S. pasterianus, previously 
belonging to the same S. bovis group as Sg).  The primers 
correctly identified all 6 Sg strains and none of the 4 non-Sg 
strains (Fig. 24a). The primers were then used in qPCR 
reactions to detect Sg in mouse colon tissues spiked with 
serially diluted Sg to establish a standard linear range (Fig. 
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24b). Mouse colon tissues without Sg were used as a control. 
This procedure was then used on ~25 pairs of colon tumor and 
matched normal tissues from CRC patients (Fig. 24c-d). The 
positive samples were further analyzed for melting temperature 
(Tm) to determine the presence of spurious amplification. Of 
the samples with the correct Tm, PCR products were purified 
using a Qiagen gel extraction kit and subject to DNA 
sequencing. The results showed that all of the products 
contained the correct Sg sequence.  
Detection of S. gallolyticus subsp. pasterianus in colon 
tumor and normal tissues from CRC patients. S. gallolyticus 
subsp. pasterianus (previously S. bovis biotype II/2) was 
closely related to Sg, however patients with endocarditis due 
to Sp did not have a strong association with CRC [13, 20, 125-
129]. Sp-specific primers were designed and tested for their 
specificity by PCR. The results showed that the primers 
correctly identified Sp but not Sg (Fig. 25a). The primers 
were then used in qPCR reactions to detect Sp in mouse colon 
tissues spiked with serially diluted bacteria to establish a 
standard linear range (Fig. 25b). The results showed that Sp 
were detected in ~8% of tumor and 12% of normal tissues.  
These percentages were much lower than those of Sg, consistent 
with previous observations (Fig. 25c-d).  
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Figure 24. Establishing a protocol for specific detection of Sg in colon 
tissues. Sg, Sm, Sp, Si, and 16sRNA primers were used to determine Sg 
primer specificity by PCR. PCR conditions are as follows: annealing 
temperature 60°C, 30 cycles (A). DNA was extracted from serially diluted Sg 
spiked mouse tissues and qPCR was performed to generate a standard curve 
as described in Materials and Methods (B). Quantification of 25 matched 
tumor and normal samples with no CT, low CT, or high CT. Cutoff for high 
CT (strong) was more than 5 CTs from the mean and cutoff for low CT (weak) 
was within 5 CTs of the mean (C-D).       
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Sg is present in the majority of CRC patients and 
preferentially associates with tumor tissues. I further 
analyzed an additional 121 tumors and 101 adjacent normal 
tissues from CRC patients.  Overall, we found that ~74% of 
tumor tissues and ~47% of the normal tissues were positive for 
Sg (p < 0.0001, tumor vs. normal, Fisher’s exact test), 
suggesting Sg is present in the majority of CRC patients and 
preferentially associates with tumor tissues (Fig. 26a, c). We 
further divided the positive samples into those with 
relatively high or low abundance of Sg. The high abundance is 
arbitrarily defined as with a 5 CT cutoff from the mean. More 
tumor tissues were highly enriched with Sg (26%) than normal 
tissues (9%) indicating a higher bacterial abundance in the 
tumor tissues (Fig. 26a-b). 
DISCUSSION: 
 McCoy and Mason first reported an association of Sg with 
CRC in 1951 and this association has since been verified by 
numerous case reports and case series. However, most reports 
are retrospective and only evaluate CRC prevalence in patients 
with an Sg infection. On the other hand, few studies have 
investigated the prevalence of Sg infections within the CRC 
population. In this study, our results demonstrate that Sg is 
found at a high prevalence within the CRC population and that 
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Figure 25. Detection of S. gallolyticus subsp. pasterianus in colon tumor 
and normal tissues from CRC patients. Sg, Sm, Sp, Si, and 16sRNA primers 
were used to determine Sp primer specificity by PCR. PCR conditions are as 
follows: annealing temperature 60°C, 30 cycles (A). DNA was extracted from 
serially diluted Sp spiked mouse tissues and qPCR was performed to 
generate a standard curve as described in Materials and Methods (B). 
Quantification of 27 matched tumor and normal samples that are positive or 
negative for Sp (C-D).       
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Figure 26. Sg is present in the majority of CRC patients and 
preferentially associates with tumor tissues. An additional 121 tumor 
tissues and 101 matched normal tissues were evaluated for the presence of 
Sg using primers and the qPCR method described previously. Quantification 
of these samples was determined based on no CT, low CT, or high CT. Cutoff 
for high CT (strong) was more than 5 CTs from the mean and cutoff for low 
CT (weak) was within 5 CTs of the mean (A-B). The number of patients with 
Sg present in only the tumor tissue, normal tissue, or both tissues was 
calculated (C).  
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Sg has a preferential association with tumor tissues vs. 
matched normal tissues.  
 In this study we developed a method for detecting Sg in 
patient samples. Previously, Sg was identified through 
biochemical analysis and conventional PCR [66]. Here, we have 
developed a sensitive and specific qPCR technique for 
detecting Sg that can be performed in a high-throughput 
manner. This technique allows for the detection of Sg and a 
determination of abundance. From this analysis, ~74% of CRC 
patients samples were positive for Sg, which is higher than 
the results reported by Adulamir et al. (32.7% in patients 
without a history of bacteremia). This may be explained by our 
study’s use of qPCR, a more sensitive technique than 
conventional PCR. Additionally, Sg has a preferential 
association with tumor tissues. In comparison, a closely 
related non-Sg strain was almost completely absent from these 
patient samples. These results corroborate previous reports in 
the literature, demonstrating a high prevalence of Sg in CRC 
cases-- showing a significantly higher prevalence of Sg over 
closely related strains. 
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Chapter 4: Sg adherence correlates with cell proliferation. 
INTRODUCTION: 
 Sg is estimated to colonize 2-15% of the normal 
population [123, 124]. However, an approximately 5-fold 
increase of Sg is seen in patients with CRC [77] and 
approximately 60% of patients diagnosed with an Sg infection 
were found to have a polyp or CRC [79]. Until recently it was 
unknown whether Sg was a cause or a consequence of CRC, but 
our group has demonstrated the tumor promoting abilities of Sg 
both in vitro and in vivo, (described in Chapter 2) further 
strengthening the importance of Sg.  
 Currently there is limited information concerning Sg 
adhesins and cell receptors responsible for Sg-host 
interactions. We have shown that Sg can adhere to CRC cell 
lines, but the mechanism of interaction has yet to be 
elucidated. Recently, a study was published that defined the 
role of Pil3B in mediating adherence to CRC cell lines and 
colonizing the mouse gut [77]. However, other factors are 
involved as demonstrated by the ability of pil3 deficient Sg 
to bind CRC cells and colonize the gut, albeit to a lesser 
degree.  
 Studies from our laboratory showed that the ability of Sg 
to promote colon cancer cell proliferation is strain 
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dependent, i.e., some Sg strains were able to promote cell 
proliferation whereas others were not (Fig. 4a, d). Here I 
characterized the ability of two of these strains to adhere to 
colon cancer cells and to colonize the mouse colon. The 
results showed that the strain that was able to promote 
proliferation also adhered more efficiently to CRC cell lines 
and more efficiently colonized the mouse gut. Additionally, 
the adherent Sg strain correlated with increased tumor burden 
in a xenograft mouse model.  
EXPERIMENTAL PROCEDURE: 
Bacterial strains and culture conditions. S. bovis group 
strains (Sg, S. pasteurianus, S. infantarius, S. macedonicus) 
were grown at 37°C in brain-heart infusion (BHI) broth with 
shaking or on BHI agar (Difco Laboratories, Sparks, MD). 
Cell lines and growth conditions. Human colon cancer cell 
line HCT116 was cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM, GIBCO, USA) supplemented with 10% fetal bovine serum 
(FBS) (GIBCO, USA).  
Adherence assay. This was performed following a procedure 
described previously with slight modifications [93]. Cells 
were seeded onto the wells of 24-well tissue culture plates at 
106 cells/well. Bacteria from a stationary phase culture were 
washed twice in PBS, resuspended in DMEM supplemented with 10% 
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FBS, and added to the wells at a multiplicity of infection 
(MOI) of 10. The plates were incubated in a humidified 
incubation chamber at 37°C with 5% CO2 for 1 hour. Each well 
was washed three times with sterile PBS to remove unbound 
bacteria. To determine the number of associated bacteria, 
cells were lysed with sterile PBS containing 0.025% Triton X-
100 and dilution plated. A β1 integrin antibody was purchased 
from Developmental Studies Hybridoma Bank and used at a 
concentration of 1.25 μg/ml or 2.5 μg/ml for adherence 
blocking experiments. All experiments were performed in 
triplicate and repeated at least three times. Adherence was 
expressed as a percentage of total bacteria added.  
Animal experiments. Animal studies were performed in 
accordance with protocols approved by the Institutional Animal 
Care and Use Committee at the Texas A&M Health Science Center, 
Institute of Biosciences and Technology. Mice were fed with 
standard ProLab IsoPro RMH3000 (LabDiet).  (1) Colonization 
model. Eight-week old female A/J or C57bl/6 mice (Jackson 
Laboratory, Bar Harbor, ME) were orally gavaged with TX20005 
or TX20008 using a feeding needle (~1 x 109 cfu/mouse) and 
then euthanized after 3 or 7 days. Colons were removed and 
frozen at -20°C until DNA extraction was performed. (2) 
Xenograft model. HCT116 cells (1 x 106) were incubated with 
TX20005 or TX20008 (MOI = 1) for 12 hours. The cells were 
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immediately washed, trypsinized and mixed with Matrigel 
(Corning, MA) according to the manufacture’s instructions and 
subcutaneously injected (100 µl) into the dorsal flap of 5-
week-old nude mice (Jackson Laboratory, Bar Harbor, ME). Three 
hours after the injection, mice were administered a broad-
spectrum antibiotic imipenem (MSD) by intraperitoneal (i.p.) 
injection (150 mg/kg body weight). Tumor diameters were 
measured with a digital caliper, and tumor volume calculated 
using the formula: Volume = (d1xd1xd2)/2, with d1 being the 
larger dimension[94]. 
Detection of Sg by qPCR. Fecal pellets were collected 
from mice at days 3 and 7. DNA was extracted using QIAamp Fast 
DNA Stool Mini Kit (Qiagen) following manufacturer’s 
instructions. DNA was extracted from frozen colons at days 3 
and 7 according to standard protocol. PCR primers were 
designed using Sg-specific sequences (forward primer – 5’ 
TGACGTACGATTGATATCATCAAC 3’, reverse primer –
5’CGCTTAACACATTTTTAGCTAATACG 3’). qPCR was performed using 
Fast Plus EvaGreen qPCR Master Mix (Biotium) in a Viia 7 Real 
Time PCR System (Applied Biosystems) with the following 
cycling condition: 95°C for 10 minutes followed by 40 cycles 
at 95°C for 30 seconds and 60°C for 1 minute. ΔCT was 
normalized to the results from qPCR reactions using universal 
16S rRNA primers.  
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RESULTS: 
The ability of Sg to adhere to cell lines correlates with 
its ability to promote cell proliferation. Unpublished data 
from our lab showed that TX20005 has the ability to promote 
cell proliferation in HCT116 cells, whereas TX20008 does not 
(Fig. 27a). We also demonstrated that the proliferation-
promoting effect of Sg requires stationary phase bacteria, and 
direct contact between bacteria and cells. Due to these 
requirements, I next examined the ability of TX20005 and 
TX20008 to adhere to HCT116 cells. I determined that TX20005 
adhered significantly better to these cells than TX20008, 
suggesting a correlation between the ability to adhere to cell 
lines and the ability to promote cell proliferation (Fig. 
27b).   
 Involvement of β1 integrin in mediating Sg adherence to 
colon cancer cells. In unpublished data we have shown that Sg 
promotes cell proliferation of HCT116 cells in a β-catenin 
dependent manner. These findings involving β-catenin were a 
pivotal step in pursuing whether Sg infection was a cause or a 
consequence of CRC, and appeared to bolster causal evidence. 
Since the β1 integrin can regulate the Wnt/β-catenin signaling 
pathway, this led us to investigate a possible role of β1 
integrin as a receptor for mediating Sg adherence.  
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Figure 27. Sg’s ability to adhere to cell lines correlates with its 
ability to promote cell proliferation. Proliferation (A) and adherence (B) 
were determined for TX20005 and TX20008 treated HCT116 cells as described 
previously. Briefly, for proliferation, 1 x 104 HCT116 cells were seeded in 
plates and incubated for 12 hours. Cells were then co-cultured with 1 x 102 
TX20005, TX20008, or no bacteria for 24 hours. Cells counts were performed 
using an automated cell counter. For adherence, TX20005 was added to wells 
containing HCT116 cells at a multiplicity of infection (MOI) of 10, as 
previously described. The plates were incubated for 1 hr. To determine the 
number of adhered bacteria, cells were lysed with sterile PBS containing 
0.025% Triton X-100 and dilution plated. Adherence was expressed as the 
percentage of adhered bacteria vs. total bacteria added. *, p < 0.05; **, 
p < 0.01; t test. 
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Adherence assays were performed in the presence of a β1 
integrin-blocking antibody to determine if Sg TX20005 adheres 
to colon cancer cells via the integrin. In comparison to 
controls, the blocking antibody significantly reduced Sg 
TX20005 adherence to HCT116 cells (Fig. 28). These results 
suggest involvement of β1 integrin in Sg adherence to CRC 
cells. Further studies are needed to confirm the involvement 
of β1 integrin in Sg adherence to colon cancer cells and to 
identify the α subunit of the integrin. 
 Sg TX20005 is more efficient at colonizing A/J mice 
colons than Sg TX20008. Next, we evaluated the ability of 
TX20005 and TX20008 to colonize the mouse colon. This was 
performed in both C57bl/6 and A/J mice and analyzed for 
bacterial burden in colon tissues. For colon tissues, I first 
evaluated Sg burden in the proximal and distal colons by 
sectioning the colon into two parts. However, we found no 
difference in Sg burden between the proximal and distal colons 
and subsequently combined proximal and distal colons for 
analysis. At 3 days post inoculation, there was no significant 
difference in bacterial burden between mice gavaged with 
TX20005 and TX20008. Similar results were seen at day 7 (Fig. 
29a). However, in A/J mice, there was a significant difference 
between TX20005 and TX20008 abundance at both days 3 and 7.  
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Figure 28. Involvement of β1 integrin in mediating Sg adherence to colon 
cancer cells. HCT116 cells were pre-treated with β1 integrin-blocking 
antibody (Developmental Studies Hybridoma Bank) at a concentration of 1.25 
μg/ml or 2.5 μg/ml or an IgG control (Cell Signaling Technologies) at a 
concentration of 2.5 μg/ml for 30 minutes in a humidified chamber at 37°C 
with 5% CO2, then washed three times with PBS to remove unbound antibody. 
TX20005 was added to wells at an MOI of 10 and incubated for 1 hr at 37°C. 
Cells were then washed three times to remove non-adherent bacteria and 
plated. Adherence was expressed as the percentage of adhered bacteria vs. 
total bacteria added and normalized to the IgG control. *, p < 0.05; **, p 
< 0.01; t test. 
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Figure 29. Colonization of mice by Sg. (A) C57bl/6 and (B) A/J mice were 
treated with Ampicillin (1g/L) in drinking water for 1 week and then 
orally gavaged with TX20005 at a dose of 1 x 109 CFU/mouse. At days 3 and 7 
post-gavage, mice were sacrificed and colons were collected. DNA was 
extracted and qPCR was performed as described in Materials and Methods for 
detection of TX20005. *, p < 0.05; **, p < 0.01; t test. 
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This may suggest that the host genetic background plays a role 
in Sg colonization. 
Sg TX20008 does not promote tumor growth in a xenograft 
model. To further evaluate the correlation between adherent 
strains and the ability to promote proliferation we evaluated 
the effects of TX20005 and TX20008 in a xenograft model. Cells 
were co-cultured with TX20005 or TX20008 for 12 hours at an 
MOI of 1 and then injected subcutaneously into the dorsal flap 
of nude mice. Mice were monitored for 17 days and tumor size 
was measured every 3-4 days. At day 7, mice injected with 
cells co-cultured with TX20005 had significantly larger tumors 
and this trend continued through day 17 (Fig. 30). 
 Investigation of the potential of TX20008 to promote 
tumor growth in the AOM-model. To further determine the tumor 
promoting effects of TX20008 in vivo, we examined its effect 
in the AOM mouse model. Mice were given 4 weekly injections of 
AOM, followed by one week of antibiotic treatment and 24 weeks 
of bacterial oral gavage. Unfortunately, mice treated with 
TX20008 did not survive. After the second bacterial gavage 3 
out of 5 mice died unexpectedly. With only two TX20008 mice 
remaining the experiment was ended, due to the lack of 
statistical value from two mice. This experiment was repeated 
and again, 8 out of 10 mice died shortly after gavages were  
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Figure 30. TX20005 promotes tumor growth in a xenograft model. ~1 x 105 
HCT116 cells were treated with TX20005 or TX20008, mixed with Matrigel and 
injected into the dorsal flap of nude mice (n=5/group) as described 
previously. Tumor size was measured during the indicated time period with 
a digital caliper (A). Mice were euthanized when tumors exceeded 15mm and 
tumors were collected for final measurements (B).   
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administered. The cause of lethality by TX20008 is currently 
unknown. 
DISCUSSION:  
CRC is one of the leading causes of cancer death, with 
over a million people diagnosed annually [30]. Recently, the 
role of microbial agents in cancer development has gained 
significant interest, with many bacteria being linked to its 
development [28, 63, 130]. Many examples from the literature 
have further increased this interest such as H. pylori in the 
development of gastric cancer [6, 130] and F. nucleatum in the 
promotion of colon cancer [46, 48, 131]. Understanding more 
details about the roles of these bacteria in cancer 
development will lead to greater prevention, earlier 
diagnoses, and improved treatment strategies.  
 Since the 1950s Sg has been associated with CRC, but it 
has not been determined whether it is a cause or a consequence 
of CRC. However, our group recently has shown that both in 
vitro and in vivo Sg leads to increased cell proliferation and 
tumor development through a currently unknown mechanism. We 
also found that direct contact between CRC cells and Sg was 
required, which led us to investigate the ability of Sg to 
adhere to CRC cells. In vitro we found that while some of our 
Sg strains were able to promote proliferation, others were 
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not. Strains that were capable of promoting proliferation were 
also capable of adhering to CRC cell lines significantly 
better. These results are consistent with our finding that 
direct contact between Sg and colon cancer cells is required 
for the bacteria to stimulate proliferation. The results also 
suggest that there is polymorphism among Sg strains with 
respect to their ability to adhere to colon cancer cells and 
to promote cell proliferation. Furthermore, it is possible 
that those Sg strains defective in cell adherence and 
promotion of cell proliferation are also defective in 
promoting tumor development in vivo. Thus, further studies to 
identify the bacterial adhesins responsible for this 
interaction and how those vary among different strains are 
needed. With respect to host receptors mediating Sg adherence, 
the result suggests a role for β1 integrin in the interaction. 
Kwok et al. in 2007 reported that H. pylori interacted with 
and activated host cells by binding to integrin α5β1 [132]. We 
were able to show through an adherence assay that when we 
treated CRC cells with a β1 integrin blocking antibody we 
significantly decreased the ability of Sg to bind to cells, 
indicating a possible role of this integrin in the Sg-CRC cell 
interaction.  Further studies such as gene knockdown or 
inhibitory or competitive ligands, are required to confirm β1 
integrin involvement.  
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 In mice, a bacterial colonization model, showed that Sg 
colonized the mouse gut; however, strain-to-strain variation 
was observed. TX20005 was better able to colonize A/J mice at 
both day 3 and day 7 post-infection than TX20008, as evidenced 
by an increased bacterial burden. Currently, the reasons for 
differences in strain colonization patterns are unknown, but 
one possibility is a differential gene expression or 
heterogeneous bacterial expression of surface adhesins. 
Previously, a study was published which underlined the 
significance of Pil3 in bacterial adherence to CRC cells and 
in bacterial colonization of the mouse distal colon [77]. When 
Pil3 was deleted decreased levels of bacterial binding and 
colonization were observed. On the other hand, over expression 
of Pil3 increased gut colonization. I have verified the 
presence of the pil3 locus by conventional PCR in both TX20005 
and TX20008 (Fig. 31). However, further analysis is needed to 
verify the sequences of these loci. Subsequently, it will be 
important to determine differences in Pil3B expression levels 
between these two strains.  
Sillanpaa et al. also noted a strong diversity among Sg 
strains and binding to ECM proteins (such as collagen I, 
collagen IV, collagen V, fibrinogen, and fibronectin), 
strongly suggesting differences in surface components of Sg 
strains [81]. Further studies should be performed to identify 
	 109	
 
                   
Figure 31. Presence of Pil3 locus in TX20005 and TX20008. Genomic DNA was 
extracted from TX20005 and TX20008 using a standard phenol/chloroform 
extraction method. Conventional PCR was performed using Pil3B primers 
constructed by Martins et al (Forward- GCAGTACATATGCAAACAGTTGACTCAGGT , 
Reverse- CCAAAGGATCCTCATGAAGGCAATTCTGCACC ). Standard PCR conditions were 
used, with an annealing temperature of 60°C and 30 cycles.  
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Sg surface components and evaluate their cognate host cell 
binding partners in order to explore colonization variation 
among Sg strains. 
 The results from the xenograft model suggest that Sg 
strains that are more adherent and more efficiently colonize 
mice also lead to increased tumor development. This reiterates 
the idea that direct bacteria-host cell contact is required 
for cell proliferation both in vitro and in vivo. Another area 
of interest is to evaluate whether Sg is a “hit and run” 
bacteria or whether its presence is required throughout 
tumorigenesis. In the literature H. pylori has been shown to 
play an important role in the early stages of tumor 
progression, but is no longer required for tumorigenesis in 
later stages [133]. Since the ability of Sg to colonize mice 
appears to play an important role in tumorigenesis it will be 
interesting to see if Sg’s presence is required at various 
stages of CRC development.  
 In summary, the data indicate variations among different 
Sg strains with respect to the ability to adhere to host 
cells, to promote cell proliferation and influences on CRC 
development. Going forward, it is important to distinguish the 
bacterial factors responsible for these processes, determine 
their surface expression patterns, and identify the mechanisms 
of these interactions among different clinical isolates. 
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Chapter 5: 
DISCUSSION: 
Sg promotes tumor development. More than 60 years after 
initial reports emerged linking Sg to CRC, the increasing 
importance of these bacteria remains a focus of studies 
investigating host-microbe interactions. In general, evidence 
for the importance of microbes in colon tumorigenesis has been 
mounting over the last several decades. While we now better 
understand the role that some of these microbes play in tumor 
promotion/development, the roles of other microbes remain 
unclear. If we can better understand the host-microbe 
interaction, this will allow us to improve upon current cancer 
diagnostics and treatments by incorporating this understanding 
into clinical strategies.  
 Although the association of Sg endocarditis/ bacteremia 
with CRC has been well documented, the nature of this 
association has remained unknown. It has been unclear whether 
Sg played a role in promoting tumorigenesis or whether it was 
an opportunistic pathogen that merely took advantage of the 
favorable tumor environment. Few experiments have been 
performed evaluating the effects of Sg on cell proliferation 
and tumor promotion until now, yet these studies hold great 
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importance in further evaluating and understanding the 
relationship between Sg and CRC. 
 From our in vitro work we were able to demonstrate that 
Sg is able to promote cell proliferation, but not apoptosis. 
This finding is important because proliferation without 
apoptosis is indicative of tumor growth. Interestingly, the 
closely related, non-Sg strains did not demonstrate the same 
proliferative effects, strongly indicating that Sg possesses 
unique properties that allow for these changes. Moreover, 
these results are consistent with what has been reported in 
the literature where the strong association with CRC was 
specific to Sg and not other closely related strains such as 
Sp and Si. Our results also indicate the importance of 
bacterial growth phase and direct bacteria-cell contact in Sg-
stimulated cell proliferation. As evidenced by our transwell 
assay, secreted bacterial factors or soluble metabolites are 
not sufficient to increase proliferation. This data suggests 
that there are specific surface components expressed by Sg 
that mediate an increase in cell proliferation and that these 
components are expressed on bacteria that are growing in the 
stationary phase. It is also possible that direct bacteria-
cell contact is required for the secretion of cytosol-
localized factors. These factors may then mediate cell 
proliferation. The specific bacterial factor(s) and host 
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receptor(s) are currently unknown, and identification of these 
factors requires further studies. 
 In the literature it is well demonstrated that a 
dysregulation of the β-catenin pathway plays an important role 
in CRC development, as it is critical in regulating cell fate 
and proliferation [98-102]. In our studies, we demonstrated Sg 
promotion of host cell proliferation through this pathway. 
First, CRC cells treated with Sg had significantly increased 
levels of nuclear β-catenin, c-Myc, and PCNA compared to an L. 
lactis control. Additionally, when the β-catenin pathway was 
inhibited by shRNA or a specific β-catenin inhibitor the 
effect of Sg on cell proliferation, c-Myc, and PCNA was 
abolished. There are many other examples in the literature of 
tumor promoting bacteria and their ability to modulate β-
catenin activity. For example, H. pylori, which is one of the 
most well understood bacteria in relation to its tumor 
promoting abilities activates β-catenin signaling. It is able 
to affect the expression of Wnt ligands [36], activate Wnt 
receptors [35], suppress GSK3β [34, 37], interfere with the β-
catenin/TCF4 complex [103-105], and disrupt the E-cadherin/β-
catenin complex [33]. F. nucleatum is another bacteria that 
has been recently linked to CRC and is shown to affect β-
catenin signaling by binding E-cadherin through its FadA 
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adhesin [50]. Additionally, S. typhi has been shown to secrete 
AvrA and activate β-catenin signaling [51].  
 Our laboratory investigated proliferative effects of Sg 
on five colon cancer cell lines: HT29, HCT116, LoVo, SW480, 
and SW1116. Our results showed Sg promoted cell proliferation 
in HT29, HCT116, and LoVo cells, all of which we term 
responsive cell lines. The other two, SW480 and SW1116, were 
unresponsive to Sg with respect to cell proliferation. 
Notably, these cell lines all contained mutations in the 
Wnt/β-catenin signaling pathway, with HT29, LoVo, SW480, and 
SW1116 having mutations in APC and HCT116 having a mutation in 
β-catenin that results in increased stability. We showed that 
Sg was able to increase β-catenin levels in HT29, HCT116, and 
LoVo cells, but not the other two cell lines. This could 
suggest that Sg activates β-catenin further upstream or 
regulates factors outside of the canonical Wnt/ β-catenin 
signaling pathway. Our adherence assays demonstrated that Sg 
can adhere to both responsive and unresponsive cells in 
similar numbers, and in some cases, can adhere better to the 
unresponsive cells lines. This indicates that the effects of 
Sg on these CRC cells may not be due strictly to adherence 
ability, but rather how Sg impacts signal transduction within 
these cells. It is also possible that Sg may bind different 
receptors in each of these distinct cell lines, therefore 
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resulting in different cellular responses, especially 
regarding β-catenin signaling. This could explain the 
differences we are seeing in cell proliferation. Overall, this 
data suggests cell context plays an important role in 
determining the effect of Sg on the cell. In a clinical 
application, this would imply that Sg may not effect all 
individuals equally, but that specific genetic or epigenetic 
backgrounds are necessary to predispose certain individuals to 
Sg-induced tumorigenesis. Therefore, it will be important to 
identify host cell receptors that are necessary for 
individuals to be affected by colonization of Sg.  
To further investigate the association of Sg with CRC, 
both xenograft and AOM mouse models were used. Results from 
both of these studies suggest an ability of Sg to promote 
tumor development. In the xenograft model, Sg treated cells 
were able to form larger tumors and resulted in higher levels 
of β-catenin, c-Myc, and PCNA. Mice in the AOM model had more 
tumors and an increased tumor burden when treated with Sg in 
comparison to the L. lactis control. Furthermore, specific 
examination of colonic crypts from the test groups 
demonstrated both a higher percentage of proliferating cells 
and increased β-catenin staining. In contrast, we saw no 
differences in staining for apoptotic cells between Sg treated 
mice and our saline or L. lactis controls. These results are 
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consistent with our in vitro analyses. We also found a 
correlation between Sg abundance in the mouse colon and tumor 
number and burden, suggesting bacterial abundance is important 
in tumor development. Additionally, Sg bacteria were detected 
within tumor tissues and appeared to be more abundant within 
these tumor tissues than surrounding normal tissues. This 
reiterates the idea that direct contact is important between 
Sg and cancer cells.  
Inflammation is known to contribute to CRC development. 
However, in our mouse experiments, Sg and L. lactis also 
induced similar levels of inflammatory responses in the mouse 
colon, as evaluated with IHC. This was further confirmed by 
cytokine profiling. This suggests that immune responses to Sg 
may not play an important role in Sg-mediated promotion of 
tumor development, but does not rule out other specific 
effects of Sg in inducing immune reactions that favor tumor 
development. It will also be interesting to examine the role 
of the gut microbiota and their relationship with Sg. While it 
appears Sg has a direct affect on tumor promotion, it is 
unknown if Sg may work in concert with other microbes to have 
this effect or if a certain microbiome makes individuals more 
susceptible to Sg-mediated tumorigeneis. Overall, our data 
supports a mechanism by which Sg increases cell proliferation 
through β-catenin up-regulation. Further studies are needed to 
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determine Sg ligands capable of binding to host cell receptors 
resulting in host cellular proliferative responses and whether 
or not the interaction of Sg with host cells is able to 
promote tumorigenesis.  
 Prevalence of Sg in CRC patients. Due to the known 
association of Sg endocarditis/ bacteremia with CRC in 
patients and our current data suggesting the ability of Sg to 
promote tumor development it is important to evaluate the 
prevalence of Sg in the CRC population. If Sg is highly 
present in CRC patients, this could provide the basis for a 
useful screening method to determine which patients are at 
risk for CRC and possibly lead to earlier detection. 
Currently, only patients with Sg endocarditis or bacteremia 
undergo further colonic evaluation, but those that are 
“silently” infected by Sg are still at risk. In addition, our 
finding that Sg promotes colon tumor development raises the 
possibility that Sg may be targeted as a part of the treatment 
to improve patient outcomes. 
 In our analysis of tumor and matched normal tissue 
samples from patients we found that significantly more tumor 
samples (74%) were positive for Sg than the matched normal 
samples (47%) and this falls within the range of previously 
reported studies. Our study looked specifically at Sg, without 
combined contributions of other closely related, non-Sg 
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strains. Additionally, 26% of the tumor samples were highly 
enriched for Sg, whereas only 9% of the normal samples were 
highly enriched, reiterating the importance of direct contact 
between Sg and cancer cells. This aligns with the findings 
from our in vitro and in vivo work. It will be interesting to 
evaluate additional samples from healthy patients with no 
pathologies to determine the prevalence of Sg in these 
patients. In comparison, Sp, a closely related strain, was 
detected in only a few samples. This data is similar to 
previous findings in the literature with Sg being the 
predominant S. bovis biotype associated with CRC. 
Additionally, we will evaluate the impact of Sg-positivity on 
global methylation as a well-described field effect for a 
subset of colorectal cancer.  
 Overall, this data suggests a strong association of Sg 
with CRC. Sg is more readily abundant in the tumor tissues of 
these patients in comparison to matched normal tissues and is 
more prevalent than a closely related Sp strain. 
Polymorphism in Sg strains. Currently, we know that a 
direct interaction between Sg and host cells is important in 
promoting cell proliferation. As a consequence, we evaluated 
the ability of several Sg strains to adhere to CRC cell lines. 
From this we found that several of these strains were able to 
adhere to CRC lines more efficiently than others and the 
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strains that adhered were able to promote cell proliferation, 
whereas those that did not were not able to. We further 
evaluated two Sg strains in both C57BL/6 and A/J mice. Sg 
strain TX20005 is adherent and TX20008 is non- or poorly 
adherent to in vitro cultured colon cancer cell lines. We 
determined colonization at three or seven days after initial 
Sg inoculation. The Sg strain that was able to adhere to cell 
lines also more efficiently colonized the colons of A/J mice 
compared to the strain that adhered poorly to in vitro 
cultured cells. We did not see this difference in C57bl/6 
mice, which suggests the host genetic background may make a 
difference in Sg colonization. Additionally, these results 
suggest that there is variation among Sg strains in terms of 
their ability to interact with colon cells and to stimulate 
cell proliferation. The specific Sg factors that mediate cell 
adherence and cell proliferation are currently unknown. In the 
literature, it has been suggested that Pil3 plays an important 
role in Sg’s ability to adhere to cells and colonize the 
distal mouse colon. It will be interesting to evaluate both 
the presence of Pil3 and expression levels between our 
adherent and non-adherent strains. Further studies are 
required to identify the bacterial and host factors involved 
in this interaction. 
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 We attempted to evaluate the ability of TX20008 to 
promote tumor development in our AOM mouse model. However, 
TX20008 was unexpectedly virulent in this model and killed 
mice before any colon tumors had the time to develop. We then 
resorted to the xenograft model. When nude mice were injected 
with cells treated with TX20005 we saw a significant increase 
in tumor size in comparison to TX20008 treated cells. Thus, it 
is important for an Sg strain to adhere to CRC cells in order 
to promote cell proliferation and to be able to colonize mouse 
tissues in order to promote tumor development.  
Implications to CRC prevention, diagnosis and treatment. 
Individuals over the age of 60 are at the highest risk for 
CRC, and currently, colonoscopy is the standard screening 
method for CRC [134]. Although this method is effective at 
detecting CRC, the compliance is low. It is estimated that 
approximately 23 million people are not up to date on their 
screening [30]. The five-year survival rate for patients with 
stage I colon cancer is 92%, but decreases significantly for 
stage IV to 11% (Table 3).  Therefore, more non-invasive 
screening methods are needed that are both reliable and 
affordable for detecting cancers early. 
Several studies have evaluated the seroprevalence of Sg 
in CRC patients. One study suggested measuring IgG antibody 
titers against Sg [8]. Sg is more abundant in fecal samples  
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Table 3: Five-year survival rate for different stages of colon 
cancer. 
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from CRC patients [119, 124, 135] and it is speculated that 
alterations at the site of the lesion allows Sg entry to the 
blood stream [136], inducing an antibody response. Also, Sghas 
been shown to highly colonize tumor lesions [83, 137] and this 
colonization deeply within the tumor tissue increases the 
likelihood of a systemic response including the production of 
IgG antibodies [66]. Other studies have suggested using ELISA-
based assays to specifically detect pilus components, in 
combination with other detectable Sg antigens, may be used to 
determine at risk groups [68]. Ultimately, knowing the 
relationship between Sg and CRC will help in further 
validating these ideas and developing better detection methods 
for CRC. The finding that Sg promotes CRC development also 
raises the possibility that Sg should be included in clinical 
strategies to treat CRC. Many questions remain in this regard. 
For example, should CRC patients be routinely screened for the 
presence of Sg? Should Sg-positive patients be treated with 
antibiotics to eliminate Sg? On the other hand, it is unclear 
whether Sg’s effect can last after its elimination from the 
gastrointestinal tract. Finally, should vaccination against Sg 
be considered? These questions require additional carefully 
planned and well-controlled studies. 
Conclusion and future directions. In summary, the results 
presented here suggest a model in which Sg mediates tumor 
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promotion through the up-regulation of β-catenin, which leads 
to increased cell proliferation. This is the first report 
providing evidence for Sg’s role in CRC. Furthermore, we 
provided additional evidence for the strong association 
between Sg and CRC in patients. Previously, studies primarily 
focused on Sg patients with endocarditis or bacteremia and the 
co-currence of CRC, but here we evaluated these patients from 
the CRC perspective to determine the prevalence within these 
patients. Finally, our results suggest that specific Sg 
factors mediate adherence to colon cells and promote cell 
proliferation. These factors are also likely to be important 
for promoting tumor development. Future studies will address 
identifying both bacterial ligands and host receptors 
responsible for the tumor promoting affects seen by Sg and 
determining the mechanism involved. These studies provide 
valuable insight into this Sg-CRC association and demonstrate 
the need for better diagnostic tests in detecting CRC. If we 
can utilize this knowledge and understand precisely how 
microbes interact with and affect the gut this will allow us 
to exploit these interactions for our benefit. 
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